

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/705, 16/28, C12N 1/20, 15/12, C12P 21/06, C12Q 1/68		A1	(11) International Publication Number: WO 99/03889 (43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/US98/14902 (22) International Filing Date: 14 July 1998 (14.07.98) (30) Priority Data: 60/052,556 15 July 1997 (15.07.97) US 60/070,741 8 January 1998 (08.01.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/052,556 (CIP) Filed on 15 July 1997 (15.07.97) US 60/070,741 (CIP) Filed on 8 January 1998 (08.01.98) (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Office of Technology Transfer, 5th floor, 1111 Franklin Street, Oakland, CA 94607 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CHANDY, K., George [US/US]; 1218 Morningside Drive, Laguna Beach, CA 92651 (US). GUTMAN, George [US/US]; 2059 Flamingo Drive, Costa Mesa, CA 92626 (US). KALMAN, Katalin			[HU/US]; 2017B Los Trencos, Irvine, CA 92612 (US). FANTINO, Emmanuelle [FR/US]; Apartment 49, 13881 Tustin East Drive, Tustin, CA 92780 (US). GARGUS, J., Jay [US/US]; 34 Urey Court, Irvine, CA 92612 (US). (74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: ISOLATED DNA ENCODING HUMAN CALCIUM ACTIVATED POTASSIUM CHANNEL**(57) Abstract**

Disclosed is an isolated DNA encoding a human small conductance calcium activated potassium channel (hKCa3/KCNN3) and the protein encoded thereby. Also disclosed is evidence that alterations in the hKCa3 gene may enhance susceptibility to schizophrenia and/or bipolar disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

ISOLATED DNA ENCODING HUMAN CALCIUM ACTIVATED POTASSIUM CHANNEL

5 **STATEMENT AS TO FEDERALLY SPONSORED RESEARCH**

This invention was made with partial Government support under Grant No. GMOD54872, awarded by Organization USPHS. The government may have certain rights in the invention.

FIELD OF THE INVENTION

- 10 This invention relates generally to the field of small conductance calcium activated potassium channels, and more specifically to the diagnosis, study, prevention and treatment of disorders related to these channels.

BACKGROUND OF THE INVENTION

- Action potentials in vertebrate neurons are followed by an after hyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the neuronal firing pattern. The AHP has several components, which are distinct are mediated by different calcium activated potassium channels. Small conductance calcium activated potassium channels (SKCa, where "S" represents "small") underlie slow components of the AHP, which are responsible for spike-frequency adaption (Hotson, J.R., and Prince, D.A., *J. Neurophysiol.* 43:409, 1980). Small conductance channels have a unitary conductance of 4-14ps, are exquisitely sensitive to internal Ca^{2+} , lack the property of voltage dependence and are blocked by nanomolar concentrations of the natural toxins apamin and scyllatoxin. These channels modulate the firing pattern of neurons via the generation of slow membrane afterhyperpolarizations (Nicoll, R.A., *Science* 241:545-551, 1988). The intermediate channels (IKCa, where "I" represents intermediate conductance) have a conductance of 11-40 pS, are blocked by charybdotoxin and clotrimazol, and are as sensitive to internal Ca^{2+} as SKCa channels

- 2 -

(Ishii, T.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:11651-11656, 1997; Joiner, W.J., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:11013-11018, 1997).

Channel dysregulation, particularly of the glutamate receptor/channels, figures
5 prominently in pathogenic mechanisms involved in many processes leading to
neurodegeneration, such as stroke, head trauma, and specific toxic drug reactions.
Glutamate is the major excitatory neurotransmitter in the CNS, and while there are five
known types of glutamate receptors, the NMDA-type ionotropic receptor/channel
complex plays the most prominent role (Sucher, N.J., *et al.*, *Trends in Pharmacological*
10 *Sciences* 17:348-55, 1996; Kaku, D.A., *et al.*, *Science* 260:1515-8, 1993).
Overstimulation of the NMDA pathway produces calcium overload and the excitotoxic
death of neurons (Choi, D.W., *Neuron* 1:623-34, 1988). The toxicity may arise through
calcium-dependent proteases or through excessive signaling, perhaps leading to
apoptosis. Extracellular Mg^{2+} produces tonic block of the NMDA receptor/channel
15 complex, and in the presence of its agonist, the receptor/channel conducts an inward
sodium and calcium current only if the membrane potential is concurrently being
depolarized (Choi, 1988, *supra*). (This paired input paradigm perhaps also forms an
elementary unit in learning, another function subserved by this receptor/channel.) As the
cytosolic calcium concentration rises, SKCa channels are activated, generating slow
20 membrane afterhyperpolarizations (Nicoll, R.A., *Science* 241:545-551, 1988; Johnson,
S.W., and Seutin, V., *Neuroscience Letters* 231:13-16, 1997). NMDA current is
physiologically terminated by this membrane repolarization, which restores the
magnesium block. Since SKCa channels regulate ion flow through the NMDA-
receptor/channel complex, they play a critical role in dampening neural excitability, and
25 may also contribute to the development of neurological diseases associated with
functional alterations in the NMDA signaling pathway (Johnson and Seutin, 1997,
supra).

The SKCa are currents that have been described in a wide range of tissues, including
brain (Lancaster, B. and Nicoll, R.A., *J. Physiol.* 389:187-203, 1987), peripheral neurons.

- 3 -

(Goh, J.W., and Pennefather, P.S., *J. Physiol.* 394:315-330, 1987), skeletal muscle (Romey, G., and Lazdunski, M., *Biochem. Biophys. Res. Commun.* 118:669-674, 1984) adrenal chromaffin cells (Neely, A., and Lingle, C.J., *J. Physiol.* 452:97-131, 1992),
5 leukocytes (Grissmer, S., *et al.*, *J. Gen. Physiol.* 99:63-84, 1992), erythrocytes (Hamill, O.P., *J. Physiol.* 319:97P-98P, 1981), colon (Lomax, R.B., *et al.*, *Gut* 38:243-247, 1996), and airway epithelia (Welsh, M.J., and McCann, J.D., *Proc. Natl. Acad. Sci. USA* 82:8823-8826, 1985). Certain types of SKCa channels have been distinguished by their sensitivities to the bee venom apamin, whereas other functionally related conductances
10 appear insensitive (Sah, P., and AclLachlan, E.M., 1992, *J. Neurophysiol.* 74:1772-1776). The distinguishing features of the SKCa channels from the maxi-K calcium activated (BK) potassium channels are the SKCa channels' low conductance (less than 50pS), the weak or negligible dependence of their activity on membrane voltage, and their high affinity for calcium ($EC_{50} < 1 \mu M$) (*e.g.*, Lancaster, B., and Zucker, R.S., *J. Physiol.*
15 475:229-239, 1994).

Recently, Imbert *et al.* reported the cloning of six novel cDNAs, each containing one or more long CAG repeats. These cDNAs were isolated from a lymphoblastoid cell cDNA expression library generated from patients with autosomal dominant cerebellar ataxia with a monoclonal antibody specific for polyglutamine sequences (Imbert *et al.*, *Nature*
20 *Genetics* 14:285, 1996). One of the cDNAs, designated AAD14, encoded the partial sequence of a putative protein of 228 amino acids in length. This polypeptide of unknown function contained two long polyglutamine stretches.

Kohler *et al.* first described a rat small conductance calcium activated potassium channel (rSKCa3) gene, and published the truncated form of the gene (Kohler *et al.*, *Science*
25 274:1709, 1996). An alignment of the known members of the small conductance calcium-activated potassium channels was described by Joiner *et al.* (*Proc. Natl. Acad. Sci.* 94:11013, 1997), who cloned the hSK4 gene, using the potassium channel signature

- 4 -

sequence (TXXTXGYG, SEQ ID NO:9). Ishii *et al.* (*Proc. Natl. Acad. Sci. USA* 94:11651-6, 1997) further cloned an intermediate conductance calcium-activated potassium channel (h1K1).

- 5 Schizophrenia is a chronic disabling disorder with a lifetime morbid risk of 1% in the general population. The illness has a significant genetic component (Kendler, K.S., In: Relatives at Risk for Mental Disorders, Dunner, D.L., Gershon, E.S., and Barrett, J.E. (eds), Raven Press, New York, pp. 247-263, 1988) and often develops in early adulthood. The disease is characterized by a constellation of symptoms including hallucinations and
- 10 delusions, disordered thinking and concentration, inappropriate emotional responses, catatonia, erratic behavior, and social and occupational deterioration. Although still controversial, "anticipation" (an increase in severity through successive generations) has been found in studies of affected families (Bassett, A.S., and Honer, W.G., *Am. J. Hum. Genet.*, 54:864-870, 1994).
- 15 Trinucleotide repeat expansions have been found to underlie several Mendelian hereditary neurological diseases (Ashley, C.T., Jr., and Warren, S.T., *Annu. Rev. Genet.*, 29:703-728, 1995; Timchenko, L.T., and Caskey, C.T., *FASEB J.*, 10:1589-1597, 1996; among others).

- Several human hereditary neurological diseases, such as Huntington's disease, fragile X
- 20 syndrome, myotonic dystrophy, spinal and bulbar muscular atrophy, Machado-Joseph disease, Friedrich's disease and spinocerebellar ataxia, are associated with expanded trinucleotide repeats (typically >35) within the coding region (e.g., Timchenko, L.T., and Caskey, C.T., *FASEB J.* 10:1589-97, 1996; Hannan, A.J., *J. Clin. Exp. Pharm. Physiol.* 23:1015-20, 1996; Bates, G., *Bioessays* 18:175-8, 1996), untranslated sequences (e.g.,
 - 25 Warren, S.T., and Ashley, C.T., *Ann. Rev. Neurosci.* 18:77-99, 1995; Tsilfidis, C., *et al.*, *Nature Genet.* 1:192-195, 1992), or introns (Campuzano, V., *et al.*, *Science* 271:1423-7, 1996) of genes. An association has been shown between the presence of anonymous CAG/CTG repeats and the development of schizophrenia and bipolar disease

- 5 -

(O'Donovan, M.C., *et al.*, *Nature Genetics* 10:380-1, 1995; O'Donovan *et al.*, *Psychological Med.* 26:1145-1153, 1996; Cardino, A.G., *et al.*, *Brit. J. Psychiatry* 169:766-771, 1996).

- 5 Intergenerational lengthening of such repeats is thought to underlie the phenomenon of "anticipation" (Ashley and Warren, 1995, *supra*) observed in schizophrenia and bipolar disease, wherein the disease worsens with subsequent generations (Johnson, J.E., *et al.*, *Amer. J. Med. Genet.* 75:275-280, 1997; Lipp, O., *et al.*, *Psychiatric Genet.* 5:S8, 1995; Serbanescu-Grigorow, M., *et al.*, *Psychiatric Genet.* 5:S10, 1995). The subset of these
- 10 mutations caused by expansions of the CAG trinucleotide have been found only within the coding region of genes, and the encoded polyglutamine arrays may occur in different places within the open-reading-frame (Housman, D., *Nature Genet.* 10:3-4., 1995). In the past few years, expanded "anonymous" CAG repeats in unidentified genes have been reported in patients with schizophrenia, with considerable overlap between allele
- 15 distributions in patients and controls (O'Donovan, M.C., *et al.*, *Nature Genetics* 10:380-381, 1995; Morris, A.G., *et al.*, *Hum. Mol. Genet.*, 4:1957-1961, 1995; O'Donovan, M.C., *et al.*, *Psychol. Med.* 26:1145-1153, 1996; O'Donovan, M.C., and Owen, M.J., *Psychol. Med.* 26:1-6, 1996; O'Donovan, M.C., and Owen, M.J., *Annals Med.* 28:541-546, 1996a).

20

SUMMARY OF THE INVENTION

- The present invention is based on the discovery and cloning of the human small conductance calcium activated potassium channel type 3 (hKCa3/KCNN3) gene, which is expressed in neuronal cells, skeletal muscle, heart, and lymphocytes. Alterations in the hKCa3/KCNN3 gene or its protein product may enhance susceptibility to
- 25 schizophrenia and/or bipolar disorder. Activators of this channel may be useful as neuroprotective agents (*e.g.*, for preventing stroke or reducing neuronal injury following head trauma) via the "physiological" inactivation of NMDA-receptor-mediated excitotoxic mechanisms. In addition, since hKCa3/KCNN3 is expressed in lymphocytes, the channel may play a role in modulating calcium-signaling during the immune

- 6 -

response. The gene is expressed in skeletal muscle and the heart where it may play a similar role in modulating signaling. Thus hKCa3/KCNN3 may be involved in neuropsychiatric, neurological, neuromuscular, and immunological disorders.

- 5 In a first embodiment, substantially purified hKCa3/KCNN3 polypeptide and isolated polynucleotides encoding hKCa3/KCNN3 polypeptides are provided. Antibodies which bind to hKCa3/KCNN3 polypeptides are also disclosed.

In another embodiment, a method for identifying a compound which affects hKCa3/KCNN3 polynucleotide or polypeptide is provided. Such compounds include
10 drugs and small molecules.

A method for diagnosis of a subject having or at risk of having a hKCa3/KCNN3-associated disorder is also provided. A method of determining the prognosis of a subject with an hKCa3/KCNN3-associated disorder is disclosed.

In another embodiment, a method of treating a subject having or at risk of having an
15 hKCa3/KCNN3-associated disorder by administering a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2 is also provided. A method of treating a patient having or at risk of having an hKCa3/KCNN3-associated disorder by introducing into a cell of the patient a nucleotide sequence encoding SEQ ID NO:2 under the control of a eukaryotic promoter so that the cell expresses SEQ ID NO:2 is provided.

- 20 A composition for administration of hKCa3/KCNN3 to a patient of a therapeutically effective amount of hKCa3/KCNN3 polypeptide is disclosed.

In an additional embodiment, a kit useful for detecting the presence of hKCa3/KCNN3 polypeptide in a sample from a subject having a hKCa3/KCNN3-associated disorder is provided. A kit useful for the detection of polynucleotide encoding hKCa3/KCNN3 in
25 a subject having a hKCa3/KCNN3 associated disorder is also provided.

- 7 -

In a further embodiment, transgenic nonhuman animals having a transgene encoding hKCa3/KCNN3 are also described.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1A-1D show the alignment of the nucleotide sequences of AAD14 (human cDNA; truncated; accession # Y08263, SEQ ID NO:3), STS-G16005 (human genomic; complete, SEQ ID NO:4), our human genomic sequence (SEQ ID NO:5), rat SKCa3 (cDNA; truncated; accession #U69884, SEQ ID NO:6), EST AA285078 (SEQ ID NO:7), and our human brain cDNA sequence (SEQ ID NO:1). The two stretches of the
10 trinucleotide repeats are bracketed. The two premature stop codons in the sequence are underlined and shown by a double asterisk (**). The two additional thymidines in the AAD14 sequence are in bold and underlined. The putative start codon for the rat SKCa3 sequence is bold and underlined. The additional nucleotide in AAD14 responsible for the frame shift is underlined, bold and shown by an asterisk (*).

15 FIG. 2A-2B shows the alignment of the amino acid sequences of rat SKCa3 (SEQ ID NO:8) and the two apparent reading frames (Fr 1; Fr 2) within hKCa3/KCNN3 (SEQ ID NO:2). The putative transmembrane segments are highlighted, and so is the pore sequence. The polyglutamine arrays are in bold.

FIG. 3A-3E is a series of graphs illustrating the distribution of CAG repeat lengths in
20 hKCa3/KCNN3 in schizophrenia patients and controls among Israeli Jews. Ordinate shows the frequency of occurrence for *all* alleles of the numbers of repeats indicated on the abscissa. FIG. 3A shows the results for Ashkenazi and Sephardic Jews combined. FIG. 3B shows the results for Ashkenazi Jews only. FIG. 3C shows the results for Sephardic Jews only. FIG. 3D shows a comparison for only the *longer* allele from all
25 subjects. FIG. 3E shows a comparison for only the *shorter* allele from all subjects. The number of subjects in each category is indicated in parentheses. Using of the Wilcoxon rank-sum test to compare each of the patient distributions (solid bars) with ethnically matched controls (stippled bars) yielded the indicated *p*-values.

- 8 -

FIG. 4A-C is a series of graphs illustrating the distribution of CAG repeat lengths for the shorter allele of schizophrenia patients related to diagnosis. FIG 4A and FIG. 4B. show the results from patients diagnosed as suffering from (FIG. 4A) "paranoid" (DSM-IV 5 295.3) or (FIG. 4B) "residual" (DSM-IV 295.6) types of schizophrenia. FIG. 4C shows the results from non-affected controls. Arrows indicate the median value for each distribution. Pairwise comparisons using the Wilcoxon rank-sum test showed a significant difference between the distributions of the shorter alleles of the "paranoid" and "residual" diagnosis groups (panel A *versus* B, $p=0.0049$), and between those of the 10 "paranoid" diagnosis group and the controls (panel A *versus* C, $p=2.1 \times 10^{-6}$).

FIG. 5A-D show the nucleotide sequence of hKCa3/KCNN3 cDNA. The 3' end of the message is marked by the poly-A region, following the poly-A signal sequence (AATAAA) which overlaps the termination codon.

FIG. 6 shows the genomic nucleotide sequence of hKCa3/KCNN3 showing the boundary 15 between the exon containing both N-terminal CAG/polyglutamine repeats, and the following intervening sequence.

FIG. 7 is a schematic diagram of genomic region containing the first exon of hKCa3/KCNN3.

FIG. 8 shows the genomic nucleotide sequence upstream of the known cDNA sequence 20 of hKCa3/KCNN3. The region of overlap with the cDNA is shown in bold.

- 9 -

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to hKCa3/KCNN3 and to the use of hKCa3/KCNN3 antibodies, nucleic acid sequences, and amino acid sequences in the study, diagnosis, 5 prevention and treatment of hSKCa-associated disorders, including neuropsychiatric, neurological, neuromuscular, and immunological disorders.

POLYNUCLEOTIDES AND POLYPEPTIDES

In one embodiment, the invention provides substantially purified hKCa3/KCNN3 polypeptide. Preferably, hKCa3/KCNN3 has an amino acid sequence set forth in SEQ 10 ID NO:2. The term "substantially purified" as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify hKCa3/KCNN3 using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the hKCa3/KCNN3 15 polypeptide can also be determined by amino-terminal amino acid sequence analysis.

Minor modifications of the hKCa3/KCNN3 primary amino acid sequences may result in proteins which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by 20 these modifications are included herein as long as the biological activity of the hKCa3/KCNN3 still exists.

The polypeptides of the invention also include dominant negative forms of the hKCa3/KCNN3 polypeptide which do not have the biological activity of hKCa3/KCNN3. A "dominant negative form" of hKCa3/KCNN3 is a polypeptide that 25 is structurally similar to hKCa3/KCNN3 but does not have wild-type hKCa3/KCNN3 function. For example, a dominant-negative hKCa3/KCNN3 polypeptide may interfere with wild-type hKCa3/KCNN3 function by binding to, or otherwise sequestering,

- 10 -

regulating agents, such as upstream or downstream components, that normally interact functionally with the hKCa3/KCNN3 polypeptide.

The invention provides polynucleotides encoding the hKCa3/KCNN3 protein as well as
5 genomic DNA sequences. These polynucleotides include DNA, cDNA and RNA sequences which encode hKCa3/KCNN3. It is understood that all polynucleotides encoding hKCa3/KCNN3 are also included herein, as long as they encode a polypeptide with hKCa3/KCNN3 activity. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, hKCa3/KCNN3
10 polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for hKCa3/KCNN3 also includes antisense sequences, and sequences encoding dominant negative forms of hKCa3/KCNN3. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all
15 degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of hKCa3/KCNN3 polypeptide encoded by the nucleotide sequence is functionally unchanged.

Specifically disclosed herein is a polynucleotide sequence containing the hKCa3/KCNN3 gene as well as the genomic DNA sequence (Figure 7). Preferably, the hKCa3/KCNN3
20 nucleotide sequence is SEQ ID NO:1. The term "polynucleotide" or "nucleic acid sequence" refers to a polymeric form of nucleotides at least 10 bases in length. By "isolated polynucleotide" is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from
25 which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule

- 11 -

(*e.g.*, a cDNA) independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double forms of DNA.

- 5 The polynucleotide encoding hKCa3/KCNN3 includes SEQ ID NO:1, dominant negative forms of hKCa3/KCNN3, and nucleic acid sequences complementary to SEQ ID NO:1. A complementary sequence may include an antisense nucleotide. When the sequence is RNA, the deoxynucleotides A, G, C, and T of SEQ ID NO:1 are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are
- 10 fragments of the above-described nucleic acid sequences that are and are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes the protein of SEQ ID NO:2 under physiological conditions or a close family member of hKCa3/KCNN3. The term "selectively hybridize" refers to hybridization under moderately or highly stringent conditions which excludes non-related nucleotide
- 15 sequences.

- In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing
- 20 regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

- An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about
- 25 room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, *e.g.*, high stringency conditions, or each of the conditions can be used, *e.g.*, for 10-15 minutes each,

- 12 -

in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

- 5 The nucleotide sequence encoding the hKCa3/KCNN3 polypeptide of the invention includes the disclosed sequence and conservative variations thereof. The term "conservative variation" as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine
- 10 for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
- 15 Given the extensive conservation of amino acid sequences between species, it would now be routine for one of skill in the art to obtain the small conductance calcium activated potassium channel nucleic acid and amino acid sequence from any species, including those provided herein (i.e., rat and human). For example, it is believed that other primate nucleic acid and amino acid sequences are now readily obtainable using the
- 20 hKCa3/KCNN3 sequence of the invention or fragments thereof as a probe. One of skill in the art can determine the percentage of sequence identity between species by aligning the encoded amino acid sequences, determining the corresponding alignment of the encoding polynucleotides, and then counting the number of residues shared between the sequences being compared at each aligned position. No penalty is imposed for the
- 25 presence of insertions or deletions, but insertion or deletions are permitted only where required to accommodate an obviously increased number of amino acid residues in one of the sequences being aligned. Offsetting insertions just to improve sequence alignment are not permitted at either the polypeptide or polynucleotide level. Thus, any insertions in the polynucleotide sequence will have a length which is a multiple of 3. The

- 13 -

percentage is given in terms of residues in the test sequence that are identical to residues in the comparison reference sequence.

Percent identify is calculated for oligonucleotides of this length by not allowing gaps in either the oligonucleotide or the polypeptide for purposes of alignment. Throughout this disclosure, whenever at least one of two sequences being compared is a degenerate oligonucleotide comprising an ambiguous residue, the two sequences are identical if at least one of the alternative forms of the degenerate oligonucleotide is identical to the sequence with which it is being compared. As an illustration, AYAAA is 100% identical to ATAAA, since AYAAA is a mixture of ATAAA and ACAAA. Methods to determine the homology and percent identity of sequences are well known in the art. These methods can be performed manually (using mathematical calculations) or with a computer program, such as BLAST (Altschul et al., 1986, Bull. Math. Bio. 48:603-616).

DNA sequences encoding hKCa3/KCNN3 can be expressed *in vitro* by DNA transfer into a suitable host cell. "Host cells" are cells in which a vector can be propagated and its DNA expressed. The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.

In the present invention, the hKCa3/KCNN3 polynucleotide sequences may be inserted into an expression vector. The term "expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the hKCa3/KCNN3 genetic sequences. Polynucleotide sequence which encode hKCa3/KCNN3 can be operatively linked to expression control sequences. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. An expression control

- 14 -

sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the gene. Both constitutive and inducible promoters, are included in the invention (see *e.g.*, Bitter *et al.*, *Methods in Enzymology* 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage γ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

- 15 -

In the present invention, the polynucleotide encoding hKCa3/KCNN3 may be inserted into an expression vector which contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg *et al.*, *Gene* 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, *J. Biol. Chem.* 263:3521, 10 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (*e.g.*, T7, metallothionein I, or polyhedron promoters).

Polynucleotide sequences encoding hKCa3/KCNN3 can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian 15 organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.

By "transformation" is meant a genetic change induced in a cell following incorporation 20 of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, the genetic change is generally achieved by introduction of the DNA into the genome of the cell (*i.e.*, stable).

By "transformed cell" is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding 25 hKCa3/KCNN3. Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently

- 16 -

treated by the CaCl_2 method using procedures well known in the art. Alternatively, MgCl_2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.

- 5 When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the hKCa3/KCNN3 of the invention, and a second foreign DNA molecule encoding a
- 10 selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).
- 15 Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.

ANTIBODIES

- 20 The hKCa3/KCNN3 polypeptides of the invention can be used to produce antibodies which are immunoreactive or bind to epitopes of the hKCa3/KCNN3 polypeptides. Antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided.

The preparation of polyclonal antibodies is well-known to those skilled in the art. See,

25 for example, Green *et al.*, "Production of Polyclonal Antisera," in: Immunochemical

- 17 -

Protocols pages 1-5, Manson, ed., Humana Press 1992; Coligan *et al.*, "Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters," in: Current Protocols in Immunology, section 2.4.1, 1992, which are hereby incorporated by reference.

- 5 The preparation of monoclonal antibodies likewise is conventional. See, for example, Kohler & Milstein, *Nature* 256:495, 1975; Coligan *et al.*, sections 2.5.1-2.6.7; and Harlow *et al.*, in: Antibodies: a Laboratory Manual, page 726, Cold Spring Harbor Pub., 1988, which are hereby incorporated by reference. Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the
- 10 presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures. Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-
- 15 established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, *e.g.*, Coligan *et al.*, sections 2.7.1-2.7.12 and sections 2.9.1-2.9.3; Barnes *et al.*, "Purification of Immunoglobulin G (IgG)," in: Methods in Molecular Biology, Vol. 10, pages 79-104, Humana Press, 1992.
- 20 Methods of *in vitro* and *in vivo* multiplication of monoclonal antibodies are well known to those skilled in the art. Multiplication *in vitro* may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally supplemented by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen
- 25 cells, thymocytes or bone marrow macrophages. Production *in vitro* provides relatively pure antibody preparations and allows scale-up to yield large amounts of the desired antibodies. Large scale hybridoma cultivation can be carried out by homogenous suspension culture in an airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture. Multiplication *in vivo* may be carried out by injecting cell

- 18 -

- clones into mammals histocompatible with the parent cells, *e.g.*; syngeneic mice, to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection.
- 5 After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.

Therapeutic applications for antibodies disclosed herein are also part of the present invention. For example, antibodies of the present invention may also be derived from subhuman primate antibody. General techniques for raising therapeutically useful

10 antibodies in baboons can be found, for example, in Goldenberg *et al.*, International Patent Publication WO 91/11465, 1991, and Losman *et al.*, *Int. J. Cancer* 46:310, 1990, which are hereby incorporated by reference.

Alternatively, a therapeutically useful anti-hKCa3/KCNN3 antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are

15 produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant

20 regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:3833, 1989, which is hereby incorporated in its entirety by reference. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones *et al.*, *Nature* 321:522, 1986; Riechmann *et al.*, *Nature* 332:323, 1988; Verhoeyen *et al.*, *Science* 239:1534, 1988; Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89:4285, 1992; Sandhu, *Crit. Rev. Biotech.* 12:437, 1992; and Singer *et al.*, *J. Immunol.* 150:2844, 1993, which are

25 hereby incorporated by reference.

- 19 -

Antibodies of the invention also may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas *et al.*, in: Methods: a Companion to Methods in Enzymology, Vol. 2, page 119, 1991; Winter
5 *et al.*, *Ann. Rev. Immunol.* 12:433, 1994, which are hereby incorporated by reference. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

In addition, antibodies of the present invention may be derived from a human monoclonal
10 antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human
15 antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green *et al.*, *Nature Genet.* 7:13, 1994; Lonberg *et al.*, *Nature* 368:856, 1994; and Taylor *et al.*, *Int. Immunol.* 6:579, 1994, which are hereby incorporated by reference.

20 The term "antibody" as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab')₂, and Fv which are capable of binding the epitopic determinant. These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows:

(1) Fab, the fragment which contains a monovalent antigen-binding fragment of
25 an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;

(2) Fab', the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule;

- 20 -

(3) $(\text{Fab}')_2$, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; $\text{F}(\text{ab}')_2$ is a dimer of two Fab' fragments held together by two disulfide bonds;

5 (4) Fv , defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and

(5) Single chain antibody ("SCA"), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain,
10 linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of making these fragments are known in the art. (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference). As used in this invention, the term "epitope"
15 binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* of DNA encoding the fragment. Antibody
20 fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $\text{F}(\text{ab}')_2$. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce
25 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patents No. 4,036,945 and No. 4,331,647, and references contained therein. These patents are hereby incorporated in their entireties by reference. See also Nisonhoff *et al.*, *Arch. Biochem. Biophys.* **89**:230,

- 21 -

1960; Porter, *Biochem. J.* 73:119, 1959; Edelman *et al.*, Methods in Enzymology, Vol. 1, page 422, Academic Press, 1967; and Coligan *et al.* at sections 2.8.1-2.8.10 and 2.10.1-2.10.4.

- 5 Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

For example, Fv fragments comprise an association of V_H and V_L chains. This
10 association may be noncovalent, as described in Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 69:2659, 1972. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. *See, e.g.*, Sandhu, *supra*. Preferably, the Fv fragments comprise V_H and V_L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing
15 a structural gene comprising DNA sequences encoding the V_H and V_L domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow *et al.*, Methods: a
20 Companion to Methods in Enzymology, Vol. 2, page 97, 1991; Bird *et al.*, *Science* 242:423-426, 1988; Ladner *et al.*, U.S. patent No. 4,946,778; Pack *et al.*, *Bio/Technology* 11:1271-77, 1993; and Sandhu, *supra*.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition
25 units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction

- 22 -

to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick *et al.*, Methods: a Companion to Methods in Enzymology, Vol. 2, page 106, 1991.

- 5 Antibodies which bind to the hKCa3/KCNN3 polypeptide of the invention can be prepared using an intact polypeptide or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or a peptide used to immunize an animal can be derived from translated cDNA or chemical synthesis which can be conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled
10 to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (*e.g.*, a mouse, a rat, or a rabbit).

If desired, polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the
15 antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan *et al.*, Unit 9, Current Protocols in Immunology, Wiley Interscience, 1991, incorporated by reference).

It is also possible to use the anti-idiotypic technology to produce monoclonal antibodies
20 which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the "image" of the epitope bound by the first monoclonal antibody.

METHOD FOR IDENTIFYING COMPOUNDS WHICH AFFECT hKCa3/KCNN3

The invention provides a method for identifying a compound which can modulate
25 hKCa3/KCNN3 activity. Drugs that modulate other ion channels have already had a major impact in the treatment of common diseases, as they provide the primary means to treat cardiac arrhythmias, epilepsy, hypertension, diabetes, and stroke. Furthermore,

- 23 -

many current drugs are useful primarily because they indirectly modulate potassium channels. The method includes incubating compounds and a sample containing hKCa3/KCNN3 polypeptide or polynucleotide under conditions sufficient to allow the components to interact, and measuring the effect of the compound on the expression or activity of hKCa3/KCNN3. In one embodiment, the sample is a cell expressing hKCa3/KCNN3 polypeptide or polynucleotide. The activity of hKCa3/KCNN3 in the sample can then be compared to the hKCa3/KCNN3 activity of a control sample not incubated with the compound. Alternatively, the effect of the compound on a signaling event (e.g., an ion flux) can be evaluated.

A "second messenger response" or "signaling event" means the generation of a biochemical or physiological response as a result of contacting the compound with a sample containing hKCa3/KCNN3 polypeptide or polynucleotide. In general, a signaling event results in the change of a molecular characteristic or parameter of the cell. Nonlimiting examples include ion fluxes (e.g., a potassium flux), enzyme activation (e.g., a serine/threonine kinase), changes in cyclic nucleotides (e.g., cAMP, cADP, cGMP, cGDP, etc.), among others. A specific, nonlimiting example of a signaling event is the generation of a K^+ flux following the interaction of a compound with hKCa3/KCNN3.

The effect of the compound on hKCa3/KCNN3 can be measured by assessing the expression of hKCa3/KCNN3 by methods well known in the art (e.g., Northern blots, see example 7). Alternatively, the effect of the compound on the activity of hKCa3/KCNN3 can be assessed by measuring the signaling event by any means known to one of skill in the art. In one embodiment, the electrophysiological properties of a cell expressing hKCa3/KCNN3 polynucleotide or polypeptide can be measured. For example, in order to determine the effect of the compound on the activity of hKCa3/KCNN3, the Ca^{2+} dependent, K^+ selective current can be measured as whole cell current from a single cell, or in membrane patches. Single channel recordings can also be used.

- 24 -

- Alternatively, a "physiological indicator" can be used to measure the signaling event. A "physiological indicator" is any compound in which a measurable property changes in a response to a physical parameter of the cell. Cell signaling events that occur *in vivo*
- 5 can be of very short duration. The physiological indicators can allow measurement of the physiological parameter over the same time period that the event actually occurs, or after the event occurs (over a longer time period). One nonlimiting example of a measurable property is a change in fluorescence of an physiological indicator in response to an ion flux.
- 10 Fluorescence is one spectral property of which can be used as the means of detecting a physiological parameter of a cell. As used herein, the term "fluorescent property" refers to the molar extinction coefficient at an appropriate excitation wavelength, the fluorescence quantum efficiency, the shape of the excitation spectrum or emission spectrum, the excitation wavelength maximum and emission wavelength maximum, the
- 15 ratio of excitation amplitudes at two different wavelengths, the ratio of emission amplitudes at two different wavelengths, the excited state lifetime, or the fluorescence anisotropy. A measurable difference in any one of these properties between a cell contacted with a compound of interest as compared to a control cell suffices to identify a compound which can modulate hKCa3/KCNN3 activity. A measurable difference can
- 20 be determined by determining the amount of any quantitative fluorescent property, *e.g.*, the amount of fluorescence at a particular wavelength, or the integral of fluorescence over the emission spectrum. Optimally, the physiological indicator is selected to have fluorescent properties that are easily distinguishable.

- A second nonlimiting example is a change in the physical location of the indicator.
- 25 Movement of the indicator can be measured by means well known to one of skill in the art. For example, fluorescence activated cell sorting can be used to identify exclusion or uptake of a physiological indicator.

- 25 -

The compounds which affect hKCa3/KCNN3 include peptides, polypeptides, chemical compounds and biological agents. Psychotropic, antiviral, and chemotherapeutic compounds can be tested using the method of the invention.

- 5 "Incubating" includes conditions which allow contact between the test compound and the hKCa3/KCNN3. "Contacting" includes in solution and solid phase. The test compound may also be a combinatorial library for screening a plurality of compounds. Compounds identified in the method of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by
- 10 any method usually applied to the detection of a specific DNA sequence, such as PCR, oligomer restriction (Saiki et al., *Bio/Technology* 3:1008-1012, 1985), allele-specific oligonucleotide (ASO) probe analysis (Conner et al., *Proc. Natl. Acad. Sci. USA* 80:278, 1983), oligonucleotide ligation assays (OLAs) (Landegren et al., *Science* 241:1077, 1988), and the like. Molecular techniques for DNA analysis have been reviewed
- 15 (Landegren et al., *Science* 242:229-237, 1988).

A compound can affect hKCa3/KCNN3 by either stimulating or inhibiting hKCa3/KCNN3. A compound "inhibits" hKCa3/KCNN3 if the ability to transport potassium is decreased. A compound "stimulates" hKCa3/KCNN3 if the ability to transport potassium is increased.

- 20 The sample can be any sample of interest. The sample may be a cell sample or a membrane sample prepared from a cell sample. Suitable cells include any host cells containing a recombinant hKCa3/KCNN3 vector of the invention. Preferably, the host cells functionally express the hKCa3/KCNN3 polypeptide, but preferably have low background potassium conductance. Alternatively, cell lines expressing hKCa3/KCNN3
- 25 polypeptide can be used. For example, Rajii or K562 cells can be used (see Example 7).

- 26 -

In one embodiment, by employing a competition between an agonist and a compound of interest, absence of a signaling event will indicate the presence of an antagonist. These assays are well known in the literature.

- 5 The binding affinities of compounds which affect hKCa3/KCNN3 can also be determined in either cells or a membrane preparation expressing hKCa3/KCNN3. In these assays, a labeled ligand is employed. A number of labels have been indicated previously (*e.g.*, radiolabels, fluorescence labels, among others) to be of use. The candidate compound is added in an appropriate buffered medium. After an incubation
- 10 to ensure that binding has occurred, the surface may be washed free of any nonspecifically bound components of the assay medium, particularly any nonspecifically bound labeled ligand, and any label bound to the surface determined. The label may be quantitatively measured. By using standards, the relative binding affinity of a candidate compound can be determined.
- 15 The antibodies and polynucleotides of the invention can be used to detect or treat a hKCa3/KCNN3-associated disorder or an hKCa3/KCNN3-related disorder. The term "hKCa3/KCNN3-associated disorder" denotes neuropsychiatric as well as non-neuropsychiatric disorders (*e.g.*, neurological, neuromuscular, and immunological disorders, among others) having a clinical appearance similar to or distinguishable from
- 20 that produced by disorders in hKCa3/KCNN3 function itself. These disorders may be understood to be caused by defects in other molecules known to participate in signaling pathways influenced by hKCa3/KCNN3, or may still have no known molecule correlate. For example, it may be that only some patients with schizophrenia have abnormal hKCa3/KCNN3 function, while others with an identical syndrome have normal
- 25 hKCa3/KCNN3 function (their syndrome presumably produced by other genetic factors). A "neuropsychiatric" disorder is a human behavior disorder (see The Merck Manual of Diagnosis and Therapy, 16th edition, p. 1532, Robert Berkow *et al.* (eds), Merck Research Laboratories, New Jersey, 1992). Examples of psychiatric disorders are the "schizophrenic disorders," which are mental disorders with a tendency toward chronicity,

- 27 -

which impair functioning and are characterized by psychotic symptoms involving disturbances of thought, perception feeling, and behavior. Another example of a psychiatric disorder is a "mood disorder" which is characterized by a pervasive
5 disturbance of mood, wherein a "mood" is a sustained emotion. A "bipolar disorder" is a mood disorder having depressive and elated or excited periods.

The invention can be used to determine the prognosis of a hKCa3/KCNN3-associated disorder. It may also be useful in guiding choices between different treatment regimens in patients with hKCa3/KCNN3-associated or -related disorders. The "prognosis" is a
10 forecast as to the probable outcome of an attack of a disease; the prospect as to recovery from a disorder as indicated by the nature and symptoms of the case. In addition, the invention may be used to identify or treat individuals who are "at risk" of developing a hKCa3/KCNN3-associated disorder. These individuals may be identified by a method of the invention for detecting the presence or absence of hKCa3/KCNN3 or by any other
15 diagnostic means, and/or may be treated by a method of the invention, prior to the actual onset of the clinical appearance of disorder. The "clinical appearance" can be any sign or symptom of the disorder.

Essentially, any disorder which is etiologically linked, as either an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, to increased expression of
20 hKCa3/KCNN3 could be considered susceptible to treatment with a hKCa3/KCNN3 suppressing reagent, and any disorder which is etiologically linked, as either an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, to decreased expression of hKCa3/KCNN3 could be considered susceptible to treatment with hKCa3/KCNN3 activating reagents, including treatments with polynucleotides encoding hKCa3/KCNN3
25 or the hKCa3/KCNN3 polypeptide itself.

For purposes of the invention, an antibody or nucleic acid probe specific for hKCa3/KCNN3 may be used to detect hKCa3/KCNN3 polypeptide (using antibody) or polynucleotide (using nucleic acid probe) in subject samples such as biological fluids,

- 28 -

cells, tissues, or nucleic acid. Any specimen containing a detectable amount of antigen or polynucleotide can be used. Examples of biological fluids of use with the invention are blood, serum, plasma; urine, mucous, and saliva. Tissue or cell samples can also be
5 used with the subject invention. The samples can be obtained by many methods such as cellular aspiration, or by surgical removal of a biopsy sample.

The invention provides a method for detecting hKCa3/KCNN3, for example, which comprises contacting an hKCa3/KCNN3 antibody or nucleic acid probe with a cell suspected of expressing the hKCa3/KCNN3 and detecting binding to the antibody or
10 nucleic acid probe. The antibody reactive with the hKCa3/KCNN3 or the nucleic acid probe is preferably labeled with a compound which allows detection of binding to hKCa3/KCNN3. The level of the hKCa3/KCNN3 in the subject cell can be compared with the level in a cell not affected by the disease process. The cell not affected by the disease process can be taken from the same subject, or can be from a control subject not
15 affected by the disease process, or can be from a cell line. Preferably the subject is human. One can distinguish the alleles of hKCa3 that are expressed, e.g., different CAG repeat lengths, point mutations.

When the cell component is nucleic acid, it may be necessary to amplify the nucleic acid prior to binding with the hKCa3/KCNN3 specific probe. Preferably, polymerase chain
20 reaction (PCR) is used, however, other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used.

The antibodies of the invention can be used in any subject in which it is desirable to administer *in vitro* or *in vivo* immunodiagnosis or immunotherapy. The antibodies of the
25 invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize antibodies of the invention are competitive and

- 29 -

non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Those of skill in the art will know, or can readily discern, an appropriate immunoassay
5 format without undue experimentation.

The antibodies of the invention can be bound to many different carriers, both soluble and insoluble, and used to detect the presence of an antigen comprising the polypeptide of the invention. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses,
10 polyacrylamides, agaroses and magnetite. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.

There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention
15 include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.

Another technique which may also result in greater sensitivity consists of coupling the
20 antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyl, puridoxal, and fluorescein, which can react with specific antihapten antibodies.

In using the monoclonal antibodies of the invention for the *in vivo* detection of antigen,
25 the detectably labeled antibody is given a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the

- 30 -

antigen comprising a polypeptide of the invention for which the monoclonal antibodies are specific.

The monoclonal antibodies or polynucleotides of the invention can be used *in vitro* and
5 *in vivo* to monitor the course of amelioration of a hKCa3/KCNN3-associated disease in a subject. Thus, for example, by measuring the increase or decrease in the number of cells expressing antigen comprising a polypeptide of the invention or changes in the concentration of such antigen present on cells or in various body fluids, it would be possible to determine whether a particular therapeutic regimen aimed at ameliorating the
10 hKCa3/KCNN3-associated disease is effective. The term "ameliorate" denotes a lessening of the detrimental effect of the hKCa3/KCNN3-associated disease in the subject receiving therapy.

THERAPEUTIC TECHNIQUES

The present invention identifies a polynucleotide sequence that can be expressed in an
15 altered manner as compared to expression in a normal cell, therefore it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. The antibodies and polynucleotides of the invention can be used to detect or to treat an hKCa3/KCNN3-associated disorder.

Detection of elevated levels of hKCa3/KCNN3 expression is accomplished by
20 hybridization of nucleic acids isolated from a cell of interest with an hKCa3/KCNN3 polynucleotide of the invention. Analysis, such as Northern Blot analysis, are utilized to quantitate expression of the hKCa3/KCNN3. Other standard nucleic acid detection techniques will be known to those of skill in the art.

Treatment can include modulation of hKCa3/KCNN3 gene expression and
25 hKCa3/KCNN3 activity by administration of a therapeutically effective amount of a reagent that modulates the hKCa3/KCNN3. The term "modulate" envisions the suppression of expression of hKCa3/KCNN3 when it is overexpressed, or augmentation

- 31 -

- of the expression of hKCa3/KCNN3 when it is underexpressed. Where a disorder is associated with the decreased expression of hKCa3/KCNN3, nucleic acid sequences that encode hKCa3/KCNN3 can be used. Where a disorder is associated with the increased
- 5 expression of hKCa3/KCNN3, nucleic acid sequences that interfere with the expression of hKCa3/KCNN3 can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of hKCa3/KCNN3 mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
- 10 Agents that block NMDA-type glutamate receptor/channels, such as ketamine, phencyclidine, and MK-801 (an experimental drug designed to be protective against excitotoxicity), induce a schizophrenia-like syndrome (Olney, J.W., and Farber, N.B., *Arch Gen Psych* 52:998-1007, 1995; Moghaddam, B., *et al.*, *J. Neurosci.* 17:2921-7, 1997; Hirsch, S.R., *et al.*, *Pharmacology, Biochemistry and Behavior* 56:797-802, 1997;
- 15 Yamamoto, J., *Psychopharmacology* 131:379-87, 1997). In contrast, many antipsychotic drugs exert an activating, agonist-like effect on NMDA receptors, either directly or in a dopamine-dependent fashion (Banerjee, S.P., *et al.*, *Neuroreport* 6:2500-4, 1995). In addition, drugs used to treat bipolar disorder type I (BPD-I), lithium and valproate, stimulate glutamate release and activate NMDA-receptors (Dixon, J.F., and Hokin, L.E.,
- 20 *Proc. Natl. Acad. Sci. USA* 94:4757-60, 1997). Based on these findings, it has been suggested that hypofunction of the NMDA-receptor signaling pathway may contribute to the pathophysiology of both schizophrenia and BPD-I (Olney and Farber, 1995, *supra*; Hirsch *et al.*, 1997, *supra*; Ishimaru, M., *et al.*, *Trends in Neurosciences* 19:416-7, 1996).

Without being bound by theory, since the physiological mechanism responsible for

25 turning off NMDA activity is a SKCa current (Nicoll, R.A., *Science* 241:545-551, 1988; Johnson, S.W., and Seutin, V., *Neuroscience Letters* 231:13-16, 1997), enhanced activity of such a potassium channel might play such a role. Increased activity would excessively hyperpolarize the membrane, induce Mg²⁺-dependent block of the NMDA-receptor, diminishing its activity. This would effectively suppress signaling via this pathway. By

- 32 -

decreasing SKCa current. by inhibiting hKCa3/KCNN3, NMDA activity could be increased.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least
5 a portion of a specific mRNA molecule (Weintraub, *Scientific American* 262:40, 1990).
In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming
a double-stranded molecule. The antisense nucleic acids interfere with the translation
of the mRNA, since the cell will not translate a mRNA that is double-stranded.
Antisense oligomers of about 15 nucleotides are preferred, since they are easily
10 synthesized and are less likely to cause problems than larger molecules when introduced
into the target hKCa3/KCNN3-producing cell. The use of antisense methods to inhibit
the *in vitro* translation of genes is well known in the art (Marcus-Sakura, *Anal. Biochem.*
172:289, 1988).

Use of an oligonucleotide to stall transcription is known as the triplex strategy since the
15 oligomer winds around double-helical DNA, forming a three-strand helix. Therefore,
these triplex compounds can be designed to recognize a unique site on a chosen gene
(Maher, *et al.*, *Antisense Res. and Dev.* 1(3):227, 1991; Helene, C., *Anticancer Drug*
Design 6(6):569, 1991).

Ribozymes are RNA molecules possessing the ability to specifically cleave other
20 single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through
the modification of nucleotide sequences which encode these RNAs, it is possible to
engineer molecules that recognize specific nucleotide sequences in an RNA molecule and
cleave it (Cech, *J. Amer. Med. Assn.* 260:3030, 1988). A major advantage of this
approach is that, because they are sequence-specific, only mRNAs with particular
25 sequences are inactivated.

There are two basic types of ribozymes namely, *tetrahymena*-type (Hasselhoff, *Nature*
334:585, 1988) and "hammerhead"-type. *Tetrahymena*-type ribozymes recognize

- 33 -

sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to *tetrahymena*-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.

The present invention also provides gene therapy for the treatment of disorders which are associated with hKCa3/KCNN3 protein. Such therapy would achieve its therapeutic effect by introduction of a therapeutic polynucleotide into cells having the disorder. The "therapeutic polynucleotide" may be polynucleotide sequences encoding hKCa3/KCNN3, or antisense polynucleotide specific for hKCa3/KCNN3, designed to treat a hKCa3/KCNN3-associated disorder. Delivery of the therapeutic polynucleotide can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Especially preferred for therapeutic delivery of antisense sequences, or hKCa3/KCNN3 polynucleotides, is the use of targeted liposomes.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). Preferably, when the subject is a human, a vector such as the gibbon ape leukemia virus (GaLV) is utilized. A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a hKCa3/KCNN3 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by attaching, for example, a

- 34 -

sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences
5 which can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the hKCa3/KCNN3 polynucleotide.

Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper
10 cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for encapsidation. Helper cell lines which have deletions of the packaging signal include, but are not limited to Q2, PA317, and PA12, for example. These cell
15 lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced.

Alternatively, NIH 3T3 or other tissue culture cells can be directly transfected with
20 plasmids encoding the retroviral structural genes *gag*, *pol* and *env*, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for the therapeutic polynucleotides is a colloidal
25 dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are

- 35 -

- useful as delivery vehicles *in vitro* and *in vivo*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm , can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley *et al.*, 1981; *Trends Biochem. Sci.* 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino *et al.*, *Biotechniques* 6:682, 1988).
- 15 The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
- 20 Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebroside, and gangliosides. Particularly useful are diacylphosphatidyl-glycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include
- 25 egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

- 36 -

The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand.

This invention involves administering to a subject a therapeutically effective dose of a pharmaceutical composition containing the compounds of the present invention and a pharmaceutically acceptable carrier. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. By "subject" is meant any mammal, preferably a human.

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate.

- 37 -

The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

- 5 The pharmaceutical compositions according to the invention are in general administered topically, intravenously, orally or parenterally or as implants, but even rectal use is possible in principle. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule
10 form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug
15 delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

- The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the
20 symptoms of the disorder and its complications. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various
25 considerations are described, e.g., in Gilman *et al.*, eds., Goodman And Gilman's: The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.

- 38 -

Thus the identification of hKCa3/KCNN3 provides a useful tool for diagnosis, prognosis and therapeutic strategies associated with expression of hKCa3/KCNN3.

TRINUCLEOTIDE REPEATS

- 5 The hKCa3/KCNN3 gene is expressed in many neuronal tissues, and small conductance calcium activated potassium channels are known to play a vital role in regulating the firing pattern of neurons via the generation of afterhyperpolarizations (*e.g.*, Nicoll, R.A., *Science* 241:545-5511, 1988). The hKCa3/KCNN3 gene has two trinucleotide arrays. Alterations in hKCa3/KCNN3 function from the expansion of the trinucleotide arrays
- 10 might affect neural excitability and contribute to the pathophysiology of various neurological and neuropsychiatric disorders, such as schizophrenia and bipolar disease. The contribution of this locus to the age of onset of symptoms and clinical presentation may vary depending on the number of trinucleotide repeats and/or mutations in the hKCa3/KCNN3 alleles.
- 15 The trinucleotide arrays in the hKCa3/KCNN3 gene can be used to diagnose or determine the prognosis of a subject having or at risk of having a hKCa3/KCNN3-associated disorder by identifying the presence and determining the number of trinucleotide repeats (*e.g.*, CAG/CTG) in the 5'-coding region of the hKCa3/KCNN3 gene. The number of trinucleotide repeats can be determined by methods well known
- 20 to one of skill in the art (*e.g.*, Speight, G., *et al.*, *Am J. Med. Genet.* 74:204-206, 1997). The number of trinucleotide repeats in the subject can then be compared with the number of trinucleotide repeats in the hKCa3/KCNN3 gene in a normal (not affected by the hKCa3/KCNN3-associated disorder) subject or a control sample, such as a cell line. In order to determine the prognosis of an hKCa3/KCNN3-associated disorder, the number
- 25 of trinucleotide repeats in the 5'-coding region of the hKCa3/KCNN3 gene from the subject can be compared to the number of trinucleotide repeats in the 5'-coding region of the hKCa3/KCNN3 gene from a series of control subjects having the hKCa3/KCNN3 disorder, wherein the prognosis for each control subject in the series is known.

- 39 -

KITS

The materials for use in the assay of the invention are ideally suited for the preparation of a kit. Such a kit may comprise a carrier means containing one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. One of the container means may comprise a probe which is or can be detectably labeled. Such probe may be an antibody or nucleic acid sequence specific for hKCa3/KCNN3, or specific fragments thereof. For example, oligonucleotide probes of the present invention can be included in a kit and used for examining the presence of hKCa3/KCNN3 in a sample, as well as the quantitative (relative) degree of binding of the probe for determining the occurrence of specific strongly binding (hybridizing) sequences, thus indicating the likelihood for an subject having or predisposed to a disorder associated with hKCa3/KCNN3.

The kit may also contain a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, fluorescent, or radionucleotide label to identify the detectably labeled oligonucleotide probe.

Where the kit utilizes nucleic acid hybridization to detect the target nucleic acid, the kit may also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence. When it is desirable to amplify the hKCa3/KCNN3 target sequence, this can be accomplished using oligonucleotide(s) that are primers for amplification. These oligonucleotide primers are based upon identification of the flanking regions contiguous with the target nucleotide sequence.

The kit may also contain a container containing antibodies which bind to hKCa3/KCNN3, or specific fragments thereof. Such antibodies can be used to distinguish the presence of hKCa3/KCNN3 or the level of expression of hKCa3/KCNN3 in a specimen. Where the kit utilizes antibodies to detect hKCa3/KCNN3, these antibodies may be directly labeled. The kit may also contain a container containing a

- 40 -

reporter means, such as avidin or streptavidin, bound to a reporter molecule such as an enzymatic, fluorescent, or radionucleotide label to identify the directly labeled antibody. Alternatively, the kit can utilize antibodies that bind hKCa3/KCNN3 that are unlabeled.

- 5 The kit may then also contain a container containing a second antibody which binds to the antibody specific for hKCa3/KCNN3. The second antibody can be directly labeled. The kit may also contain a container containing a reporter means, such as avidin or streptavidin, bound to a reporter molecule such as an enzymatic, fluorescent, or radionucleotide label to identify the directly labeled second antibody.

10 TRANSGENIC ANIMALS

In another embodiment, the present invention relates to transgenic animals having cells that express hKCa3/KCNN3. Such transgenic animals represent a model system for the study of hKCa3/KCNN3 related disorders and the study of hKCa3/KCNN3 based therapeutics.

- 15 The term "animal" here denotes all mammalian species except human. It also includes an individual animal in all stages of development, including embryonic and fetal stages. Farm animals (pigs, goats, sheep, cows, horses, rabbits and the like), rodents (such as mice), and domestic pets (for example, cats and dogs) are included within the scope of the present invention.
- 20 A "transgenic" animal is any animal containing cells that bear genetic information received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by microinjection or infection with recombinant virus. "Transgenic" in the present context does not encompass classical crossbreeding or *in vitro* fertilization, but rather denotes animals in which one or more cells receive a recombinant DNA molecule.
- 25 Although it is highly preferred that this molecule be integrated within the animal's chromosomes, the present invention also contemplates the use of extrachromosomally replicating DNA sequences, such as might be engineered into yeast artificial chromosomes.

- 41 -

The term "transgenic animal" also includes a "germ cell line" transgenic animal. A germ cell line transgenic animal is a transgenic animal in which the genetic information has been taken up and incorporated into a germ line cell, therefore conferring the ability to transfer the information to offspring. If such offspring in fact possess some or all of that information, then they, too, are transgenic animals.

It is highly preferred that the transgenic animals of the present invention be produced by introducing into single cell embryos DNA encoding hKCa3/KCNN3, in a manner such that the polynucleotides are stably integrated into the DNA of germ line cells of the mature animal and inherited in normal Mendelian fashion. Advances in technologies for embryo micromanipulation now permit introduction of heterologous DNA into fertilized mammalian ova. For instance, totipotent or pluripotent stem cells can be transformed by microinjection, calcium phosphate mediated precipitation, liposome fusion, retroviral infection or other means, the transformed cells are then introduced into the embryo, and the embryo then develops into a transgenic animal. In a preferred method, developing embryos are infected with a retrovirus containing the desired DNA, and transgenic animals produced from the infected embryo.

In a most preferred method the appropriate DNAs are coinjected into the pronucleus or cytoplasm of embryos, preferably at the single cell stage, and the embryos allowed to develop into mature transgenic animals. These techniques are well known. For instance, reviews of standard laboratory procedures for microinjection of heterologous DNAs into mammalian (mouse, pig, rabbit, sheep, goat, cow) fertilized ova include: Hogan *et al.*, Manipulating the Mouse Embryo, Cold Spring Harbor Press, 1986; Krimpenfort *et al.*, *Bio/Technology* 9:86, 1991; Palmiter *et al.*, *Cell* 41:343, 1985; Kraemer *et al.*, Genetic Manipulation of the Early Mammalian Embryo, Cold Spring Harbor Laboratory Press, 1985; Hammer *et al.*, *Nature*, 315:680, 1985; Purcel *et al.*, *Science*, 244:1281, 1986; Wagner *et al.*, U.S. patent No. 5,175,385; Krimpenfort *et al.*, U.S. patent No. 5,175,384, the respective contents of which are incorporated by reference.

- 42 -

The cDNA that encodes hKCa3/KCNN3 can be fused in proper reading frame under the transcriptional and translational control of a vector to produce a genetic construct that is then amplified, for example, by preparation in a bacterial vector, according to
5 conventional methods. See, for example, the standard work: Sambrook *et al.*, Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, 1989, the contents of which are incorporated by reference. The amplified construct is thereafter excised from the vector and purified for use in producing transgenic animals.

The term "transgenic" as used herein additionally includes any organism whose genome
10 has been altered by *in vitro* manipulation of the early embryo or fertilized egg or by any transgenic technology to induce a specific gene knockout. The term "gene knockout" as used herein, refers to the targeted disruption of a gene *in vivo* with complete loss of function that has been achieved by any transgenic technology familiar to those in the art. In one embodiment, transgenic animals having gene knockouts are those in which the
15 target gene has been rendered nonfunctional by an insertion targeted to the gene to be rendered non-functional by homologous recombination. As used herein, the term "transgenic" includes any transgenic technology familiar to those in the art which can produce an organism carrying an introduced transgene or one in which an endogenous gene has been rendered non-functional or knocked out.

20 The transgene to be used in the practice of the subject invention is a DNA sequence comprising a modified hKCa3/KCNN3 coding sequence. In a preferred embodiment, the endogenous SKCa3 gene is disrupted by homologous targeting in embryonic stem cells. For example, the entire murine SKCa3 gene may be deleted. Optionally, the SKCa3 disruption or deletion may be accompanied by insertion of or replacement with other
25 DNA sequences, such as a non-functional hKCa3/KCNN3 sequence. In other embodiments, the transgene comprises DNA antisense to the coding sequence for hKCa3/KCNN3. In another embodiment, the transgene comprises DNA encoding an antibody or receptor peptide sequence which is able to bind to hKCa3/KCNN3. Where appropriate, DNA sequences that encode proteins having hKCa3/KCNN3 activity but

- 43 -

differ in nucleic acid sequence due to the degeneracy of the genetic code may also be used herein, as may truncated forms, allelic variants and interspecies homologues.

5

EXAMPLES

The following examples are intended to illustrate but not to limit the invention in any manner, shape, or form, either explicitly or implicitly. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.

10

Example 1

Gene Isolation Methods

A homology search was carried out for the human homolog of the newly discovered rat cDNA encoding a portion of the rSKCA3 channel (rat small conductance calcium-activated potassium channel, type 3) (accession # U69884). In a BLAST cDNA database
15 search, the N-terminal regions of the rat cDNA encoding features of the channel not shared with other classes of potassium channels was used as a probe sequence. Such probes detected the 3' untranslated region of an anonymous cDNA sequence, AAD14 (accession #Y08263). Approximately 95% of the putative coding sequence of the human homolog was found. This sequence had 89% identity with the rat SKCa3 sequence
20 (FIGS. 1 and 3). Identity is only 45% and 40%, respectively, with the SKCa1 (accession # U69883) and SKCA2 (accession # U69882) channels, suggesting that this is truly the homolog of the type 3 channel.

The human genomic database was surveyed for anonymous sequence tagged sites (STSs) for homology with the AAD14 cDNA sequence. It identified a clone, STS-G16005, that
25 aligns with nucleotides 328-940 of the cDNA. This region of the cDNA encodes not only the first 128 bp of the hKCa3/KCNN3 sequence as one ORF, but it also encodes the anonymous ORF that AAD14 was originally reported to contain. That original ORF has two polyglutamine stretches encoded by perfect CAG repeats (12 and 14 in length). The two ORFs contained on this genomic and cDNA sequence are out of frame and separated

- 44 -

by a single stop codon. Removing one nucleotide eliminates the stop codon and joins both ORFs into a single ORF within the same exon.

To test this idea, the region was sequenced multiple times (n=6) in normal human
5 genomic DNA. Rather than the reported string of eight Cs (position 632-640 in FIG. 1),
seven were repeatedly identified. Deletion of this additional C from the AAD14
sequence put the two ORFs in-frame (FIG. 2, AAD14 Fr.1). This indicates that the
authentic initiator methionine for hKCa3/KCNN3 resides at least 800 bp farther upstream
than that published for the rat homolog (Kohler, M., *et al.*, *Science* 273:1709-1714,
10 1996), and the hKCa3/KCNN3 protein contains two polyglutamine stretches in its
N-terminus.

This region from normal human genomic DNA was amplified using the polymerase
chain reaction (PCR). By sequencing the relevant fragments it was confirmed that the
ORF containing the polyglutamines was transcribed from a single exon, and were able
15 to demonstrate the first and second CAG arrays were polymorphic. The primers used for
PCR are described below and have utility for diagnosis. Comparison of the AAD14
cDNA sequence with that of the genomic fragment of hKCa3/KCNN3 and STS-G16005
also demonstrated polymorphism of the two CAG arrays. The second polyglutamine
repeat is 14 residues long in AAD14 but 19 residues long in both genomic sequences; the
20 first polyglutamine repeat is two residues longer in AAD14 and STS-G16005 than the
genomic sequence of hKCa3/KCNN3.

Comparison of the translated protein sequences of hKCa3/KCNN3 and its rat homologue
(rSKCa3) shows 14 amino acid differences in the first 278 residues of the published rat
sequence, many of them being conservative substitutions (FIGS. 2 and 4). The presence
25 of two additional thymidines in the AAD14 nucleotide sequence compared to that of its
rat homologue and the hKCa3/KCNN3 sequence (FIGS. 1 and 3) introduces an apparent
premature stop codon in the AAD14 ORF; these extra Ts are located within
polypyrimidine tracts and most likely represent sequencing errors. This notion is

- 45 -

reinforced by the hKCa3/KCNN3 sequence data and observing that translation of the remaining 313 base pairs of the AAD14 sequence reveals a second ORF that is again identical to the rat SKCa3 sequence, with one conservative substitution at 291 (FIGS. 2 and 4). To test this idea, this region from normal human brain cDNA was amplified and the relevant region sequenced. As shown in Figure 3, the additional T's are not present in the sequence. Removal of these additional nucleotides puts the known coding region in the AAD14 cDNA in one reading frame (FIGS. 2 and 4). These two adjacent ORFs reflect the single ORF encoded in the hKCa3/KCNN3 channel.

- 10 The AAD14 cDNA is an incomplete sequence and does not contain the initiator methionine or the last 0.5 kb at the 3'-end. PCR was therefore used to isolate an overlapping hKCa3/KCNN3 fragment from human brain cDNA (Marathon cDNA, Clontech) that contained the entire 3'-end of the coding region by PCR (FIGS. 1 and 3). The human and rat genes show a high degree of conservation in this region (FIGS. 3 and 15 4). The isolation of three hKCa3/KCNN3 clones from human lymphocytes (accession numbers Y08263, AA284005; AA285078) suggests that this gene might encode one of the lymphocytic SKCa channels that have been reported to play an important modulatory role in calcium signaling involved in mitogen-induced activation.

Example 2

20 Expression in vitro

- In a further construct, the 3' end of the hKCa3/KCNN3 gene was spliced into the AAD14 cDNA at a unique SphI site. A methionine was placed at the 5'-end of the coding region and the clone was placed under control of the SP6 promoter. A cRNA from this construct or from the DNA sequence corresponding to this construct was expressed in 25 mammalian cells in order to characterize the biophysical and pharmacological properties of the channel. This construct, when expressed in mammalian cell lines or amphibian oocytes, serves as an extremely valuable tool for high-throughput screening studies to identify hKCa3/KCNN3-specific modulating agents; or agents that specifically alter other channels whose activity is a function of hKCa3/KCNN3 activity, such compounds

- 46 -

might have therapeutic value for the treatment of schizophrenia, bipolar disorder, or other neuropsychiatric disorders. Since hKCa3/KCNN3 was initially isolated from lymphocytes, it might encode the small conductance calcium-activated potassium
5 channels in these cells that play an important role in mitogen-induced activation; hKCa3/KCNN3-blockers might therefore be useful as immunosuppressive agents.

Example 3

Diagnostic Test Methods

Pairs of PCR primers (listed below in table) were designed to that would allow
10 amplification from genomic DNA the region of the hKCa3/KCNN3 gene flanking the CAG repeats. These primer pairs were used sequentially. First the two unlabeled primers, 22QA and 22QB were used, and the resultant products were cloned into the TA cloning vector (PCRII, Invitrogen) and manually sequenced using as sequencing primers oligonucleotides based on vector sequence. This sequencing confirmed that both CAG
15 repeats were polymorphic in the population.

For example, these PCR products, or nested PCR products produced by primers directed to the internal sequence, could be formed using either fluorescent-labeled primers or fluorescent nucleotides to form products of this reaction that could be run on an acrylamide gel in an automated sequence analysis system with fluorescence detection
20 (Pharmacia) to resolve the size of the PCR product. This would reflect the number of the CAG repeats in the gene.

- 47 -

Table 1 - PCR Primers

	Primer	Length	Start	End	Sequence	Notes
5	22QA	23	339	361	ACCCCAAGTGCCCCTGTCCATCC (SEQ ID NO:10)	Upstream of repeats
	22QB	24	782	805	ATCTCCGTGAAGGGGTTGCTGTC C (SEQ ID NO:11)	Between stop codon and SK3 ATG
	22QC	24	589	612	CTGAAAGCGGTGGGAGAGGAGT GC (SEQ ID NO:12)	Make 274bp PCR product with QA3
	22QD	26	414	439	CACCGTCAGTGTCCACGATAGTC CC (SEQ ID NO:13)	For sequencing of stop codon region

NB: positions indicated on the Y08263 DNA (=AAD14)

- 48 -

PCR ReactionsReagents:

	Taq Polymerase Buffer 10X (Gibco)
5	50 Mm Mg ²⁺ (Gibco)
	Taq Polymerase 5U/ μ l(Gibco)
	dNTPs mix 10mMach (Gibco)
	DNA human genomic 1 μ g/ μ l
	primer 22QA 100ng/ μ l
10	primer 22QB 100ng/ μ l

Reactions:

	5	μ l Taq Pol Buffer 10X
	1.5	μ l Mg ²⁺ 50mM
	1	μ l dNTPs 10mM
15	5	μ l primer 22QA
	5	μ l primer 22QB
	31.5	μ l H ₂ O
	1	μ l genomic DNA (or positive control DNA)
	50	μ l final volume
20	+0.25	μ l Taq Polymerase 5U/ μ l

Cycling conditions:

1 cycle	3 min	94 °C
40 cycles	30 sec	94 °C
	30 sec	65 °C
25	1 min	72 °C

10-15 μ l of each reaction is analyzed on a 2% agarose gel in 1xTAE.

- 49 -

Example 4**Association between length of CAG repeats and schizophrenia**

The human *KCa3* gene contains two adjacent polyglutamine repeat arrays in its N-terminal region (Chandy, K.G., *et al.*, *Molec. Psych.* 3:32-37, 1998, herein incorporated by reference); this feature has been subsequently recognized in the rat gene as well (GenBank accession numbers AF031815, U69884). Interestingly, the two polyglutamine arrays are linked by a proline-rich region containing the motif *PXXP* repeated five times, and this segment may be targeted by signaling molecules possessing SH3 domains (Kuriyan, J., and Cowburn, D., *Annu. Rev. Biophys. Biomol. Struct.* 26:259-288, 1997). The second polyglutamine repeat is highly polymorphic in Caucasian European and North American populations, ranging from 10-28 repeats in length, with a modal value of 19 repeats (Chandy *et al.*, 1998, *supra*; Bowen, T., *et al.*, *Mol. Psych.* 3:32-37, 1998, herein incorporated by reference). Case-control analyses have recently shown a significant over-representation of longer *hKCa3/KCNN3* CAG-repeat alleles in Caucasian schizophrenia patients compared with ethnically matched controls (see Example 8).

1. Materials and methods

Subjects: This study was performed after approval by the local Ethics Committee, and all subjects provided informed consent permitting use of their DNA for research. One hundred sixty five Jewish schizophrenic patients meeting DMS-IV criteria for schizophrenia (24) were recruited among patients hospitalized in Abarbanel Mental Health Center, Bat-Yam, Israel. Diagnoses were made during hospitalization by structured interviews, and confirmed in clinical interviews during the study period by a consensus of at least two board certified psychiatrists. Diagnoses were established prior to the genetic study, and patients were not included if there was any disagreement in diagnosis. Israeli controls were recruited from our anonymous "DNA bank" obtained from 154 healthy Jewish individuals at least 20 years of age who had no history of psychiatric disease.

- 50 -

Statistical analysis. The Wilcoxon Rank-Sum test with tied midranks (Lehmann, E.L., Nonparametrics: statistical methods based on ranks, McGraw-Hill, New York, 1975) was used to compare pairs of frequency distributions. For comparison of multiple
5 distributions the Kruskal-Wallis test (Lehmann, ,1975, *supra*) was used. Testing for correlation was done by the *t*-test (Armitage, P., and Berry, G., Statistical Methods in Medical Research, 2nd Ed., Blackwell Scientific Publications, Oxford, 1987). Computer programs to carry out these tests were kindly provided by Dr. Howard Tucker (Department of Mathematics, University of California, Irvine). The Fisher Exact test on
10 dichotomized data was carried out using the IRFIS program (GG), and the 95% confidence interval on the odds ratio calculated according to Woolf (Woolf, B., *Ann. Hum. Genet.* 19:251-253, 1955).

Allele sizing. Genomic DNA was prepared from 10 ml of peripheral blood (Miller, S.A., *et al.*, *Nucl. Acid. Res.* 16: 1215, 1988). DNAs were amplified by PCR using the
15 following primers:

forward 5' GCAGCCCCTGGGACCCTCGCT 3' (SEQ ID NO:14)

reverse 5' ACATGTAGCTGTGGAAGTTGGAGAGT 3' (SEQ ID NO:15)

The expected product size is about 300 bp, and depends on the number of CAG repeats in the polymorphic 3'-most of the two clusters in the N-terminal region of
20 *hKCa3/KCNN3/KCNN3*. ³²P-dCTP in was used in the reaction mixture in a total volume of 15 µl, and DMSO (final 10%) was added to inhibit nonspecific amplification products. Conditions of PCR were 30 cycles at 94°C for 30 seconds, 65°C for 30 seconds, 72°C for 45 seconds, following initial denaturation at 94°C for 3 min.

The PCR products were diluted in formamide loading buffer, denatured at 70°C for 10
25 min and loaded onto a denaturing sequencing gel. The PCR product sizes were determined by comparison with an M13 sequencing ladder and internal controls consisting of three cloned and sequenced alleles of known repeat length (Chandy, K.G., *et al.*, *Molec. Psych.* 3:32-37, 1998). The trinucleotide repeats often do not appear as single discrete DNA bands on polyacrylamide gel, but rather as one major band

- 51 -

accompanied by one or more stutter bands owing to PCR artifacts; in such cases, the strongest band for each allelic form was used for the determination. The presence of a single band was scored as a homozygous allele. All genotyping was carried out in a
5 blinded fashion with control and patient samples randomly mixed together. The length assignment of several samples was independently confirmed.

2. Association between length of CAG repeats and schizophrenia in Israeli Jews

The number of CAG repeats in the second CAG region of the *hKCa3/KCNN3/KCNN3* gene was analyzed in 165 Israeli Jewish schizophrenia patients and in 154 unaffected
10 Jewish controls. FIG. 1A shows the frequency of alleles with different CAG repeat lengths for all patients with schizophrenia and unaffected controls. This repeat is highly polymorphic in both populations, with an overall range of alleles from 4 to 25 CAGs. The modal allele for the control group is 18 CAG repeats, unlike the modal allele of 19 repeats reported in European and North American Caucasians (see Example 8). The
15 modal allele for Israeli Jewish patients with schizophrenia is 19 CAG repeats, and the 3 longest alleles (23-25 repeats) are uniquely represented among patients. Using the Wilcoxon Rank Sum test it was found that the distributions of alleles are significantly different between patients and controls ($p < 10^{-6}$). Dichotomizing the sample at the overall modal allele of 19 CAG repeats (Chandy *et al.*, 1998, *supra*), and applying the Fisher
20 Exact test, also shows a highly significant excess of longer alleles in patients compared with controls ($p < 10^{-6}$, odds ratio (OR) = 4.9, 95% confidence interval (CI) = 3.1-7.8).

This association was further analyzed by separately comparing CAG repeat lengths in 84 Ashkenazi Jewish patients with 102 ethnically matched controls, and 75 Sephardic Jewish schizophrenia patients with 39 controls; subjects whose parents were of mixed
25 ethnic origins were excluded from this analysis. The distribution of alleles is significantly different between Ashkenazi schizophrenia patients and controls using the Wilcoxon test (FIG. 3B, $p = 1.7 \times 10^{-4}$). A similar analysis reveals a significant difference between Sephardic Jewish schizophrenia patients and ethnically matched controls (FIG. 3C; $p < 10^{-6}$). Dichotomization of the sample at the modal allele (19 repeats) and analysis by

- 52 -

the Fisher Exact test revealed a significant excess of longer alleles in both Sephardic and Ashkenazi schizophrenia patients compared with ethnically matched controls (Sephardim, $p < 10^{-6}$, OR=13, 95% CI 4.1-45; Ashkenazim, $p = 2.9 \times 10^{-5}$, OR=3.2, 95% CI 1.8-5.6). Thus, the differences between patients and controls in these Jewish populations are far more robust than those found in more heterogeneous European and North American Caucasian populations (Chandy *et al.*, 1998, *supra*; and Example 8).

3. Association between length of CAG repeats and schizophrenia in males and females.

The population was separately analyzed according to sex (data not shown). A comparison of female schizophrenia patients ($n = 67$) with female controls ($n=108$), showed a highly significant excess of longer alleles in patients ($p < 10^{-6}$ by Wilcoxon and Fisher Exact). A similar comparison of 98 male patients and 46 male controls also revealed a highly significant difference between patients and controls, ($p < 10^{-6}$ by Wilcoxon and Fisher Exact). There was no significant difference between the allele distributions of males versus females, among patients or controls, using either the Wilcoxon or Fisher Exact tests.

4. Both alleles are associated with schizophrenia.

The allele distributions shown in Figs. 3A-C include *both* alleles from each individual. To determine if only one or both alleles in any individual contribute to disease risk, the allele distributions of the *longer* (FIG. 3D) and *shorter* (FIG. 3E) alleles were separately compared in each of 165 schizophrenia patients and 154 unaffected controls. *Both* the shorter and the longer alleles from each subject were significantly longer in schizophrenia patients than controls, using either the Wilcoxon test ($p = 1.6 \times 10^{-5}$ for the shorter; $p < 10^{-6}$ for the longer) or the Fisher Exact test on dichotomized data ($p < 10^{-6}$ for both; OR=3.31, 95% CI=2.1-5.5 for the shorter allele; OR=5.36, 95% CI=3.1-9.2 for the longer allele). The distributions of the *sum* of the two alleles (data not shown) were also significantly longer in schizophrenia patients compared with controls (Wilcoxon, $p < 10^{-6}$, Fisher Exact $p < 10^{-6}$, OR=4.5, 95% CI =2.4-8.5). When the Sephardim and Ashkenazi populations are considered separately, the long allele makes a greater contribution to

disease susceptibility in Sephardim (Fisher Exact: $p \leq 10^{-6}$, OR = 19, 95% CI 4.3-85.6) than in Ashkenazim (Fisher Exact: $p = 8.2 \times 10^{-5}$, OR = 3.6, 95% CI 1.9-7.0). Likewise, while the overall contribution to disease risk is less for the shorter of two alleles than the longer, its contribution is greater in Sephardim (Fisher Exact: $p = 0.0076$, OR=9.5, 95% CI=1.2-75) than in Ashkenazim (Fisher Exact: $p = 0.047$, OR=4.5, 95% CI=0.9-22).

5. Type of schizophrenia, disease severity and CAG repeat length.

Several types of schizophrenia are recognized based on differences in clinical features, prognosis and response to medication. The genetic factors that enhance disease susceptibility of each of these forms of schizophrenia may differ, and it is therefore possible that the CAG repeat length in the *hKCa3/KCNN3* gene may vary with diagnosis. The patient pool used in the above studies included substantial representation within only four of these categories, namely those with DSM-IV diagnoses 295.1 ("disorganized"), 295.3 ("paranoid"), 295.6 ("residual") and 295.7 ("schizoaffective disorder"). The Kruskal-Wallis test was applied to this group of four allele distributions (Table 2) which revealed a statistically significant difference between them ($p=0.021$). Carrying out separate comparison for the longer and shorter allele in each patient indicated that the distributions for the longer alleles were not significantly different from one another ($p=0.60$). On the other hand, the distributions of the shorter alleles (Table 3) were significantly different ($p=0.027$). Pairwise comparisons (Wilcoxon test) showed statistically significant differences between "paranoid" and "residual," the two largest groups among our patient population ($p=0.005$), as well as between the "paranoid" and "schizoaffective disorder" groups ($p=0.025$). No other pairwise comparison within this table yielded a significant difference.

- 54 -

TABLE 2^a

	CAGs,		DSM-IV Diagnosis:			
	all alleles:	<u>295.1</u>	<u>295.3</u>	<u>295.6</u>	<u>295.7</u>	<u>totals</u>
5	4	0	0	1	0	1
	13	1	3	3	0	7
	14	0	2	3	2	7
	15	2	6	6	2	16
	16	4	4	3	2	13
10	17	2	5	7	1	15
	18	5	11	14	2	32
	19	14	27	30	7	78
	20	16	45	30	6	97
	21	7	21	11	1	40
15	22	2	6	0	1	9
	23	0	1	1	0	2
	24	1	0	1	0	2
	25	<u>0</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>1</u>
		54	132	110	24	320

20

^a Distribution of lengths of CAG repeats in *hKCa3/KCNN3* of patients (*all* alleles) grouped according to their DSM-IV diagnosis. There is a significant difference between these distributions (overall $p=0.021$ by the Kruskal-Wallis test).

- 55 -

TABLE 3^a

	CAGs, shorter allele: <u>295.1</u>		DSM-IV Diagnosis			<u>totals</u>
			<u>295.3</u>	<u>295.6</u>	<u>295.7</u>	
5	4	0	0	1	0	1
	12	1	2	2	0	5
	13	0	2	3	2	7
	14	1	6	6	2	15
	15	4	4	2	1	11
10	16	2	3	7	1	13
	17	1	4	5	0	10
	18	5	7	10	3	25
	19	7	23	16	2	48
	20	5	12	3	1	21
15	21	<u>1</u>	<u>3</u>	<u>0</u>	<u>0</u>	<u>4</u>
		27	66	55	12	160

^a Distribution of lengths of CAG repeats in *hKCa3/KCNN3* of patients (*shorter* allele only) grouped according to their DSM-IV diagnosis. There is a significant overall difference between these distributions ($p=0.027$ by the Kruskal-Wallis test). Pairwise comparisons using the Wilcoxon test showed a significant difference between the distributions of subjects with diagnoses of 295.3 ("paranoid" type) and 295.6 ("residual" type; $p=0.0049$), and between 295.3 and 295.7 ("schizoaffective disorder"; $p=0.025$).

This diagnosis-related difference between the *shorter* alleles in schizophrenia patients is graphically illustrated in FIG. 4. The distributions for those patients diagnosed with "paranoid" (DSM-IV 295.3) and "residual" (DSM-IV 295.6) types of disease, the two most frequent diagnosis among the subjects (FIG. 4A and FIG. 4B) are displayed together with that of the shorter alleles of the unaffected controls (FIG. 5C). The shift in the median values of these distributions (indicated by arrows) is evident. The Wilcoxon test on pairwise comparisons showed a significant difference between the distributions in panels A and B ($p=0.0049$), and between panels A and C ($p=2.1 \times 10^{-6}$).

The relationship between length of CAG repeats (using *all* alleles) and the severity of disease as measured by the total number of recorded hospitalizations was also determined. Examining the distributions shown in Table 4 by the Kruskal-Wallis test

- 56 -

revealed no significant association ($p=0.78$). Lastly, the relationship between CAG repeat length and age at first hospitalization, a measure of the age-of-onset of disease, was determined. A very weak but statistically significant *positive* correlation (*i.e.*,
5 between longer alleles and later age of onset) was found by a two-tailed t-test for all alleles ($p=0.0025$, $r=0.17$), as well as for the longer allele ($p=0.024$, $r=0.17$) and the shorter allele ($p=0.0047$, $r=0.22$) in each patient analyzed separately.

In this study, a striking difference was found in the CAG repeat length in the *hKCa3/KCNN3/KCNN3* gene between Israeli Jewish patients with schizophrenia and
10 ethnically matched controls. Both alleles in an individual contribute to disease risk, and patients diagnosed with "paranoid" or "disorganized" types of schizophrenia appear to have longer repeats than patients with other forms of this disease. This difference is evident both in Ashkenazi and Sephardic Jews, as well as in males and females. The magnitude and statistical significance of these differences is substantially
15 greater than those obtained in previously reported studies on Caucasian populations from France, the United Kingdom, Ireland and North America (Example 8 and Chandy *et al.*, 1998, *supra*). This may be the result of a higher degree of genetic homogeneity within these Jewish populations (Karlin, S., *et al.*, *Am. J. Hum. Genet.* 31:341-365, 1979), and there are distinct and well-established advantages to studying a more
20 homogeneous population when confronted with the inherent complexity of identifying alleles of small effect in a polygenic disorder. Decreasing the population variance at other contributing loci may highlight the effect produced by the locus under investigation.

- 57 -

TABLE 4^a

		Number of hospitalizations:			
	#CAGs:	<u>1-4</u>	<u>5-9</u>	<u>>9</u>	<u>totals</u>
5	4	0	1	0	1
	12	3	0	2	5
	13	5	4	0	9
	14	4	8	3	15
	15	4	3	5	12
10	16	8	2	7	17
	17	5	6	2	13
	18	13	15	19	47
	19	45	33	26	104
	20	26	27	19	72
15	21	7	11	5	23
	22	1	1	3	5
	23	1	0	1	2
	24	2	0	0	2
	25	<u>0</u>	<u>1</u>	<u>0</u>	<u>1</u>
20		124	112	92	328

^a Distribution of lengths of CAG repeats in *hKCa3/KCNN3* of patients (*all* alleles) grouped according to the total number of hospitalizations. There is no significant difference between these distributions ($p=0.48$ by the Kruskal-Wallis test).

25

Example 5

Expression of hKCa3/KCNN3/KCNN3 transcripts in human tissues

1. Materials and methods

Northern blot and in situ analysis: Northern blots of RNA from human tissues (multiple organs, lymphoid tissues, regions of brain and established cell lines) were obtained from Clontech (Palo Alto, CA), hybridized with a *hKCa3/KCNN3*-specific probe (~500 bp *Apal* fragment, nucleotides 330-825 of the 5' coding region), and washed at a final stringency of 0.1 X SSC, 0.1% SDS for 30-40 min. at 55°C. All blots were exposed at -80°C with an intensifying screen for 15 days.

- 58 -

Histological material came from the brains of two normal adults with no history of drug abuse or neurological illness and no evident Alzheimer's pathology. Blocks of the upper brainstem and basal ganglia were cut from fresh-frozen coronal slabs of each brain (Jones, E.G., *et al.*, *J. Neurosci. Methods* 44: 133-44, 1992). For *in situ* hybridization, each block was raised to 4°C over 20 minutes, fixed in cold 4% paraformaldehyde in 0.1 M phosphate buffer for ~24 hours at 4°C, then infiltrated with 30% sucrose, re-frozen in dry ice, and sectioned serially in the frontal plane on a freezing microtome at 40 µm. Free-floating sections were hybridized with 1x10⁶ cpm/µl of (α-³²P-UTP)-labeled, anti-sense (or sense) riboprobes transcribed from a linearized cDNA template, using a previously described protocol (Akbarian, S., *et al.*, *Cerebral Cortex* 5:550-6, 1995). cRNA probe concentration and specific activity were approximately the same in all *in situ* runs. Sense controls gave weak background labeling only, comparable to that seen over the white matter. After hybridization, the sections were exposed to β-Max autoradiographic film (Amersham, Arlington Heights, IL) for 10-14 days. After film development, slides were dipped in Kodak NTB2 photographic emulsion, exposed at 4°C for 6 weeks, developed in Kodak D19 developer, fixed with Kodak Rapid Fix and counter-stained with cresyl violet.

2. Results.

The findings of Example 6 above demonstrate a strong association between the CAG repeat length and the development of schizophrenia in Israeli Jews. An understanding of the mechanisms by which CAG repeats in *hKCa3/KCNN3/KCNN3* might affect the risk of developing schizophrenia requires knowledge of where this gene is expressed within human tissues, and how its distribution might relate to disease symptoms. Thus Northern blot and *in situ*-hybridization studies were used to probe diverse human tissues with an *hKCa3/KCNN3/KCNN3*-specific DNA fragment.

Among a variety of human tissues examined, Northern blot analysis revealed expression to be largely limited to brain, striated muscle and lymphoid tissues. Two predominant transcripts (~9 and ~13 kb) were found in human brain, heart and skeletal

- 59 -

muscle, and in lymph-node and spleen; some smaller mRNA species were also visible, for example in skeletal muscle and spleen. Interestingly, several ESTs encoding *hKCa3/KCNN3* have been isolated from human lymphocytes (accession numbers
5 AA491238, Y08263, AA285078, AA284005), and the human T-cell line Jurkat expresses a K_{Ca} channel with pore properties similar to those of *hKCa3/KCNN3* (Grissmer, S., *et al.*, *J. Gen. Physiology* 99:63-84; Grissmer, S., *et al.*, *J. Gen. Physiology* 102:601-630, 1993). Screening a panel of transformed cell lines revealed abundant expression of a ~2.5 kb *hKCa3/KCNN3* transcript in the Rajii B-cell line and
10 the erythroleukemic cell K562; fainter transcripts of varying sizes were seen in other cell lines (HL-60: promyelocytic leukemia; HeLa (S3): epithelial carcinoma; MOLT-4: lymphoblastic leukemia; SW480: colorectal adenocarcinoma; A549: lung carcinoma; G361: malignant melanoma.

Within the brain, a relatively high intensity of *hKCa3/KCNN3* mRNA was detected
15 in the human substantia nigra, basal ganglia, and subthalamic nuclei. The human hippocampus and amygdala, two regions previously implicated in affect and psychosis (Moghaddam, B., *et al.*, *J. Neurosci.* 17:2921-2927, 1997; Hirsch, S.R., *et al.*, *Pharmacol., Biochem. Behav.* 56:797-802, 1997), also show abundant expression of *hKCa3/KCNN3*. Only lower levels of *hKCa3/KCNN3* expression are seen in the
20 cerebral cortex, cerebellum and thalamus.

Consistent with these findings, *in situ* hybridization studies on sections of human midbrain more precisely localized *hKCa3/KCNN3* transcripts to the human substantia nigra and ventral tegmental area. *hKCa3/KCNN3* mRNA was also found in the putamen, but not in the red nucleus, cerebral peduncle or globus pallidus. This
25 distribution is consistent with *hKCa3/KCNN3* being expressed in dopaminergic neurons of the nigrostriatal and mesolimbic pathways that have previously been implicated in schizophrenia (Haber, S.N., and Fudge, J.L., *Schiz. Bull.*, 23:471-482, 1997). The dopamine D_2 receptor is also primarily localized in these pathways, and the affinity of antipsychotic drugs for this specific isoform of the dopamine receptor

- 60 -

appears to correlate with their clinical potency (Seeman, P., and Tallerico, T., *Mol. Psych.*, 3:123-134, 1998).

3. Discussion

- 5 A theory put forward by Perutz *et al.* (Perutz, M.F., *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:5355-5358 35-37, 1994) regarding expanded CAG repeats contribute to the pathogenesis of schizophrenia, suggests that polyglutamine repeats behave as polar zippers, and that proteins begin to oligomerize once the repeat length progresses beyond a critical threshold of 35 to 40 repeats. Does the hKCa3/KCNN3 channel fit
- 10 Perutz's "rule of 35"? Functional potassium channels are tetramers, and the N- and C-termini are located within the cytoplasm (Ishii, T.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:11651-1165, 1997; Spencer, R.H., *et al.*, *J. Biol. Chem.* 27:2389-239, 1997). If each hKCa3/KCNN3 monomer contained the modal number of glutamines in the second repeat (*i.e.*, 18 repeats), the tetramer would contain 72 glutamines from this
- 15 region. An additional 48 glutamines would be contributed by the first repeat (12 per monomer) and another 20 by the short polyglutamine stretch in the C-terminus (5 per monomer). Such an hKCa3/KCNN3 tetramer would therefore display 140 glutamines contained within repeats on its cytoplasmic surface, which is greater than that of the longest allele seen in Huntington's disease (121 repeats). Since K_{Ca} channels are able
- 20 to form heteromultimers as well as homomultimers (Ishii *et al.*, 1997, *supra*), hKCa3/KCNN3 proteins with short and long polyglutamine repeats are likely to co-assemble. An individual carrying two different hKCa3/KCNN3 alleles would have a diversity of expressed channels, including two kinds of homotetramers, and various heterotetramers with differing combinations of long- and short-repeat subunits. In
- 25 addition, heteromultimers formed from combinations of hKCa3/KCNN3 and other members of the family, will provide another level of heterogeneity in channel phenotype. If each of these channels has distinct biophysical properties, regulation of the cell's membrane potential will be determined by the behavior of a complex ensemble of hKCa3/KCNN3 channels.

- 61 -

Since hKCa3/KCNN3 channels are expressed in restricted regions of the brain, it is easy to envision a pathogenic mechanism involving subtle alterations in channel function (and therefore neuronal membrane potential) produced by tetrameric channels containing a larger number of polyglutamines. Alterations in membrane potential (and therefore neuronal behavior) might occur once a critical "threshold" has been crossed. Thus, both alleles of an individual contribute to the formation of functional K_{Ca} channels and would therefore be expected to be associated with disease. This expectation is consistent with our finding of a shift toward longer repeats for *both* alleles in individuals with schizophrenia (FIG. 1D and E).

Expanded CAG alleles are generally dominant in those neurodegenerative diseases in which they have been implicated, and the phenotype they produce is qualitatively different from that of null alleles; the pathogenicity of such expanded polyglutamine repeats is therefore thought to be the result of a novel "gain-of-function." If longer polyglutamine repeats in hKCa3/KCNN3 enhance channel function in a graded manner, one might expect the membrane potential of neurons expressing these channels to be excessively hyperpolarized, leading to a progressive lengthening in the inter-spike interval and an alteration of neuronal excitability. If this is true, one might expect to see a relationship between CAG repeat length and some manifestation of disease phenotype. Two of the findings provide at least some support for this expectation. First, we observe a relationship between the length of CAG repeats and the type of schizophrenia exhibited is observed; greater length of the *shorter* allele in affected individuals is associated with the "paranoid" and "disorganized" types of schizophrenia, compared with the "residual" and "schizoaffective disorder" forms of disease (Table 3, FIG. 2). Additionally, we find a very weak correlation between allele length and the age at first hospitalization, although no significant relationship between allele length and the number of hospitalizations (Table 4). The weakness of such associations may reflect at least in part the relative insensitivity of our current measures of disease severity (Johnson, J. E., *et al.*, *Am. J. Med Genetics* 74:275-80, 1997), as well as a degree of subjectivity involved in establishing the different types

- 62 -

of diagnoses (Diagnostic and statistical manual of mental disorders: DSM-IV, 4th ed., American Psychiatric Association, Washington DC., 1994).

Which neuronal pathways in the brain could be modulated by hKCa3/KCNN3 channels
5 and contribute to the pathophysiology of schizophrenia? Although SKCa and IK_{Ca}
channels are structurally and functionally similar, they each have distinct patterns of
tissue expression. In the rat brain, KCa3 has the narrowest regional expression in the
family, with KCa2 being widely expressed, and KCa4 not being expressed in neuronal
tissue. The observations of these experiments on the distribution of hKCa3/KCNN3
10 in the human brain are consistent with the major findings in the rat (Köhler, M., *et al.*,
Science 273:1709-1714, 1996). The relative intensity of hKCa3/KCNN3 expression in
the human substantia nigra, ventral tegmental area, basal ganglia, subthalamic nuclei,
amygdala and hippocampus suggests a role for this channel in two of the four major
dopaminergic pathways in the human brain, pathways that have been implicated in
15 schizophrenia. The nigrostriatal pathway connects the substantia nigra to the caudate
and putamen while the mesolimbic pathway connects the ventral tegmental area to the
amygdala and hippocampus. Defects in these dopaminergic pathways are thought to
contribute to the pathophysiology of schizophrenia, and to the psychomotor disorders
characteristically associated with the disease. It is of note that these two pathways
20 encompass the very limited region of the CNS that expresses dopamine D₂ receptors,
and that the clinical potency of antipsychotic drugs appears to correlate with their
affinity for this specific isoform of the dopamine receptor. The human hippocampus
and amygdala are two regions also previously implicated in affect and psychosis
(Moghaddam, B., *et al.*, *J. Neurosci.* 17: 2921-2927, 1997; Hirsch, S.R., *et al.*,
25 *Pharmacol., Biochem. Behav.* 56:797-802, 1997); *in vivo* and postmortem imaging
studies of schizophrenia patients have repeatedly shown a reduction in the volume of
the amygdala and hippocampus compared with controls. Only low levels of
hKCa3/KCNN3 expression are seen in the cerebral cortex, cerebellum and thalamus,
regions that receive inputs from the tegmentum and include the third major
30 dopaminergic pathway (mesocortical) implicated in schizophrenia.

- 63 -

Since schizophrenia is a polygenic disease and is thought involve 5-10 different genes (Karayiorgou, M., and Gogos, J.A., *Neuron* 19:967-79, 1997); it is clearly important to determine the contribution of hKCa3/KCNN3 to disease risk, one measure of which is the odds ratio. The odds ratio for the allelic association of hKCa3/KCNN3 and schizophrenia from dichotomized data is substantial; both in Sephardim (OR=13 for all alleles, OR = 19 for longer allele only) and Ashkenazim (OR=5.0 for all alleles, OR=3.6 for longer allele). These values are significantly greater than those observed in earlier studies with more heterogeneous European and North American Caucasians (OR = 2.4, Chandy *et al.* (1998, *supra*); OR = 1.4, Bowen *et al.* (1998, *supra*), suggesting that hKCa3/KCNN3 is a more important risk factor for schizophrenia among Israeli Jews, and more so among Sephardic than Ashkenazi Jews.

Example 6

Association between a polymorphic CAG repeat in the hKCa3/KCNN3 gene and schizophrenia

In a further investigation, 194 patients meeting DSM-III-R criteria for schizophrenia and 183 controls matched for age and sex were studied (Bowen *et al.*, *Mol. Psychiatry* 3:266-269, 1998, herein incorporated by reference). All of the patients were Caucasians born in the UK or Eire. The patients included single affected individuals from 129 families containing two or more cases of schizophrenia. The remaining 65 subjects were recruited from inpatient and day hospitals in South Wales. The patient group consisted of 135 males and 59 females, mean age of 45 years (s.d. 13). Diagnoses were made using OPCRIT version 3.31 using all available data including a semistructured interview and case notes. Age-at-onset was defined as age at first psychiatric contact. Controls consisted of 123 males and 60 females with a mean age of 43 years (s.d. 12). The controls were matched to probands for age, sex and ethnicity from more than 700 blood donors.

Published primers for the CAG repeat corresponding to the CHLC marker GTC10H06 (Gastier, J.M., *et al.*, *Genomics* 32:78-85, 1996) were purchased from Gibco BRL

- 64 -

(Paisley, Scotland). PCR was carried out using high molecular weight genomic DNA isolated from lymphocytes by phenol/chloroform extraction. Reproducible amplification was achieved using an MJ PTC 110-96 VH thermocycler. The following
5 protocol was utilized: denaturation at 94°C for 5 min., followed by an initial cycle of 94°C for 1 min., 65°C for 2 min., and then 72°C for 1 min. for primer annealing. The primer-annealing temperature was then reduced over the next 12 cycles by 0.5°C per cycle to a final value of 59°C. This was followed by 22 cycles consisting of 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute. Reactions were carried
10 out in a volume of 12.5µl of 1X PCR buffer containing 1.5 mM MgCl₂, 40 ng DNA, 0.6 µM primers (where the forward primer was 5' end labeled with γ-³²P dATP), 0.08 mM dNTPs and 0.5 U of Taq polymerase. PCR products were electrophoresed on 6% polyacrylamide gels, and used for autoradiographic analyses. Descriptive statistics for the allele distribution in schizophrenic subjects were as follows: mean repeat size 18.4
15 (s.d. 1.9), median 19, range 13-23. Results are shown in Table 5.

- 65 -

Table 5

Numbers of each size of allele in patients and controls
(frequencies in brackets)

5	Repeat number	Control	Schizophrenia
	13	14 (0.038)	21 (0.054)
	14	15 (0.041)	6 (0.015)
	15	3 (0.008)	3 (0.008)
	16	6 (0.016)	13 (0.034)
10	17	52 (0.142)	39 (0.101)
	18	80 (0.219)	89 (0.229)
	19	131 (0.358)	129 (0.332)
	20	36 (0.098)	52 (0.134)
	21	22 (0.060)	24 (0.062)
15	22	6 (0.016)	8 (0.021)
	23	1 (0.003)	0
	24	0	3 (0.008)
	30	0	1 (0.003)
	total	366	388

- 20 When the alleles were dichotomized into ≤ 19 and > 19 , schizophrenic probands had a higher frequency of alleles with > 19 repeats than did controls ($\chi^2 = 2.820$, 1 d.f., $P = 0.047$, 1-tail). However, a comparison of the allele frequency distributions did not meet conventional levels of significance (i.e., $P \leq 0.05$) (Mann-Whitney $U = 67440$, $W = 134601$, $P = 0.11$ (1-tail)). No association was found between repeat size and
- 25 gender in the schizophrenic samples, but a later age-at-onset was associated with larger allele size (Mann-Whitney $U = 2625.5$, $W = 6084.5$, $P = 0.046$ (2-tail)), contrary to expectations.

- 66 -

The data provide support for an association between moderately large CAG repeats in the hKCa3/KCNN3 gene and schizophrenia. Although a lesser trend was found for larger repeats in this patient group under the comparison of the overall allele frequencies, dichotomization of the sample according to Chandy *et al.* (*Mol. Psych.* 3:32-37, 1998), which was justified by the previous hypothesis, revealed a result that meets the convention criteria of $p \leq 0.05$.

Although a positive association between the length of the CAG trinucleotide repeat and schizophrenia was noted, it cannot be assumed that the polyglutamine sequence in the channel is directly involved in increased susceptibility in schizophrenia, although this is one hypothesis. It is possible that the polymorphic repeat is merely in linkage disequilibrium with a disease related polymorphism which lies elsewhere in the hKCa3/KCNN3 gene or in a neighboring gene.

Example 7

Transgenic Mice Expressing hKCa3/KCNN3

Transgenic mice that can produce hKCa3/KCNN3 are made according to methods well known in the art. For example, young female mice are injected with hormones to induce superovulation, and are mated. The one-celled embryos are collected, and the pronuclei injected with a purified DNA solution containing the constructs which encode hKCa3/KCNN3. The injected eggs are cultured briefly, and re-implanted into pseudopregnant female mice. Genomic DNA is prepared from each progeny, and analyzed by PCR or Southern blot to determine the mouse's genotype. Mice who carry the transgene are subsequently mated in order to produce a line of mice.

Using these method mice are produced which contain transgenes encoding hKCa3/KCNN3. In order to target the expression to specific cell types, transgenic mice are produced which carry genes encoding hKCa3/KCNN3 under the control of specific promoters. Examples of such constructs are genes encoding SEQ ID NO:2 under the control of the neurofilament light promoter sequences (Charron, G., *et al.*,

- 67 -

J. Biol. Chem. 270:25739-25745, 1995); which specifically target the expression of hKCa3/KCNN3 to neurons.

Although the invention has been described with reference to the presently preferred
5 embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

- 68 -

What is claimed is:

1. A substantially purified human small conductance calcium-activated potassium channel -3 (hKCa3/KCNN3) polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.
2. An isolated polynucleotide encoding an hKCa3/KCNN3 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.
3. An isolated polynucleotide selected from the group consisting of:
 - (a) SEQ ID NO:1, where T can also be a U;
 - (b) nucleic acid sequences complementary to SEQ ID NO:1;
 - (c) fragments of SEQ ID NO:1 that are at least 15 bases in length and will hybridize to DNA which encodes a polypeptide as set forth in SEQ ID NO:2.
4. The polynucleotide of claim 2, wherein said polynucleotide is operatively linked to an expression control sequence.
5. The polynucleotide of claim 4, wherein the expression control sequence is a promoter.
6. The polynucleotide of claim 5, wherein the promoter is tissue specific.
7. An expression vector containing the polynucleotide of claim 2.
8. The vector of claim 7, wherein the vector is a plasmid.
9. The vector of claim 7, wherein the vector is a viral vector.

- 69 -

10. The vector of claim 9, wherein the viral vector is a retroviral vector.
11. A host cell containing the vector of claim 7.
12. The host cell of claim 11, wherein the cell is a eukaryotic cell.
13. The host cell of claim 11, wherein the cell is a prokaryotic cell.
14. An antibody which binds to an hKCa3/KCNN3 polypeptide having an amino acid sequence as set forth in SEQ ID NO:2 or conservative variants thereof.
15. The antibody of claim 14, wherein the antibody is monoclonal.
16. The antibody of claim 14, wherein the antibody is polyclonal.
17. A method for identifying a compound which affects hKCa3/KCNN3, comprising:
 - (a) incubating the compound and a sample of interest, wherein said sample contains a member of the group consisting of hKCa3/KCNN3 polypeptide and hKCa3/KCNN3 polynucleotide, under conditions sufficient to allow the compound of interest to interact with the sample;
 - (b) determining the effect of the compound on the expression or activity of hKCa3/KCNN3.
18. The method of claim 17, wherein the sample of interest is a host cell containing an expression vector comprising an isolated polynucleotide encoding the hKCa3/KCNN3 polypeptide encoding SEQ ID NO:2.

- 70 -

19. The method of claim 17, wherein the sample of interest is a cell line expressing an hKCa3/KCNN3 polypeptide.
20. The method of claim 17, wherein the sample of interest is hKCa3/KCNN3 polypeptide having an amino acid sequence as set forth in SEQ ID NO:2.
21. The method of claim 17, wherein the sample of interest is a polynucleotide encoding SEQ ID NO:2.
22. The method of claim 17, wherein the compound is selected from the group consisting of a peptide, peptidomimetic, chemical compound, and a pharmaceutical compound.
23. A method for diagnosis of a subject having or at risk of having a hKCa3/KCNN3-associated disorder, comprising the steps of :
 - (a) contacting a sample from the subject suspected of having or at risk of having a hKCa3/KCNN3-associated disorder with a reagent that binds to hKCa3/KCNN3,
 - (b) detecting binding of the reagent to hKCa3/KCNN3,
 - (c) comparing the binding of the reagent to said sample with the binding of the reagent to a control sample.
24. The method of claim 21, wherein the sample is nucleic acid.
25. The method of claim 24, further comprising amplifying the nucleic acid of the sample prior to contacting a sample from the subject suspected of having a hKCa3/KCNN3 disorder with a reagent that binds to hKCa3/KCNN3.

- 71 -

26. The method of claim 21, wherein the sample is a biopsy, blood, plasma, serum, or urine.
27. The method of claim 21, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
28. The method of claim 21, wherein the disorder is bipolar disease.
29. The method of claim 21, wherein the disorder is schizophrenia.
30. The method of claim 21, wherein the reagent is an antibody which binds to hKCa3/KCNN3 polypeptide.
31. The method of claim 21, wherein the reagent is a polynucleotide which encodes SEQ ID NO:2.
32. The method of claim 21, wherein the reagent is detectably labeled.
33. The method of claim 32, wherein the detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound.
34. A method of diagnosis of a subject having a hKCa3/KCNN3-associated or at risk of having a hKCa3/KCNN3-associated disorder comprising:
 - (a) identifying the presence of a trinucleotide repeat in the 5'-coding region of the hKCa3/KCNN3 gene; and
 - (b) comparing the trinucleotide repeat region from the subject with the same region from a normal subject or a standard sample, thereby providing a diagnosis of the subject.

- 72 -

35. The method of claim 34, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
36. The method of claim 34, wherein the disorder is schizophrenia.
37. The method of claim 34, wherein the disorder is bipolar disease.
38. A method of determining the prognosis of a subject with an hKCa3/KCNN3-associated disorder, comprising:
 - (a) obtaining a sample from said subject,
 - (b) determining the number of a trinucleotide CAG/CTG repeats in the 5'-coding region of the hKCa3/KCNN3 gene;
 - (c) correlating the number of a trinucleotide repeats in the 5'-coding region of the hKCa3/KCNN3 gene in said subject with the prognosis of the subject.
39. The method of claim 38, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
40. The method of claim 38, wherein said disorder is schizophrenia.
41. The method of claim 38, wherein said disorder is bipolar disease.
42. The method of claim 38, wherein said sample consists of a biopsy, blood, plasma, or urine sample obtained from said subject.

- 73 -

43. The method of determining a treatment regimen of neuropsychiatric, neurological, neuromuscular or immunological disorders in a subject with an hKCa3/KCNN3-associated disorder, comprising:
- (a) obtaining a sample from said subject,
 - (b) determining the number of a trinucleotide CAG/CTG repeats in the 5'-coding region of the hKCa3/KCNN3 gene,
 - (c) correlating the number of a trinucleotide repeats in the 5'-coding region of the hKCa3/KCNN3 gene in said subject with the prognosis of the subject.
44. The method of claim 43, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
45. The method of claim 43, wherein said disorder is schizophrenia.
46. The method of claim 43, wherein said disorder is bipolar disease.
47. The method of claim 43, wherein said sample consists of a biopsy, blood, plasma, or urine sample obtained from said subject.
48. A method for determining the prognosis of a subject diagnosed with an hKCa3/KCNN3-associated disorder, comprising:
- obtaining a sample from said subject,
 - determining the alleles of hKCa3 expressed in said sample from said subject, and
 - correlating the alleles with the prognosis of said subject.

- 74 -

49. The method of claim 48, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
50. The method of claim 48, wherein said disorder is schizophrenia.
51. The method of claim 48, wherein said disorder is bipolar disease.
52. The method of claim 48, wherein said sample is a member selected from the group consisting of a biopsy, blood, plasma, or urine sample
53. A method for treating a subject having or at risk of having an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, comprising administering to the subject a therapeutically effective amount of a polypeptide of SEQ ID NO:2.
54. The method of claim 53, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
55. A method of treating a subject having or at risk of having an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2.
56. The method of claim 55, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.

- 75 -

57. A method of treating a patient having or at risk of having an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, the method comprising:
introducing into a cell of a patient having an hKCa3/KCNN3-associated disorder a nucleotide sequence encoding a SEQ ID NO:2 and a eukaryotic promoting sequence operably linked thereto, said introducing resulting in the genetic transformation of the cell so that the nucleotide sequence expresses SEQ ID NO:2.
58. The method of claim 57, wherein the disorder is selected from the group consisting of a neuropsychiatric, neurological, neuromuscular, and immunological disorder.
59. A composition for administration of hKCa3/KCNN3 to a patient having an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder comprising:
(a) a therapeutically effective amount of a substantially pure hKCa3/KCNN3 polypeptide; and
(b) a pharmaceutically acceptable carrier.
60. The composition of claim 55, wherein the carrier is a liposome.
61. A kit useful for detecting the presence of hKCa3/KCNN3 in a sample from a subject having a hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, the kit comprising: carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a container containing an antibody which specifically binds to hKCa3/KCNN3.

- 76 -

62. A kit useful for the detection of a target nucleic acid sequence in a sample from a subject having a hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder, wherein the presence of the target nucleic acid sequence in the sample is indicative of having or predisposed to having a human hKCa3/KCNN3-associated disorder, the kit comprising: carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a container containing oligonucleotides which hybridize to hKCa3/KCNN3 nucleic acid sequences.
63. A transgenic nonhuman animal having a phenotype characterized by expression of hKCa3/KCNN3, otherwise not naturally occurring in the animal, the phenotype being conferred by a transgene contained in the somatic and germ cells of the animal, the transgene comprising a nucleic acid sequence which encodes hKCa3/KCNN3.
64. The transgenic nonhuman animal of claim 63, wherein the animal is a mouse.

[illegible]

FIGURE 1B

hSkca3	CAGGGCCCCCCC TTCGTCCAACTCCACCGCCATCCTCCACCCTTCCTCC AGGCAAGGCAGCCAGCTCA	700
AAD14	-----C-----T-----	700
G16005	A-----NN--NC-----A--NN-----C-----	373
R69884	-----T--AAT- -AG-----A-----	415
hSkca3	ATCTCAATGACCACTTGCTTGGCCACTCTCCAAGTTCACAGCTACAAGTGGGCCTGGCGGAGGCAGCCG	770
AAD14	-----T-----T-----	770
G16005	-----	443
R69884	-----G-----C-----T-----	485
hSkca3	GCACCGACAGGCCAGCCCCCTGGTGCACCGGCGGGACAGCAACCCCTTCACGGAGATCGCCATCAGCTCC	840
AAD14	-----	840
G16005	-----	513
U69884	-----	9
R69884	-----G-----G-----T-----A--T-----	555
hSkca3	TGCAAGTATAGCGGTGGGGTCATGAAGCCCCCTCAGCCGCTCAGCGCTCCCGGAGGAACCTCATCGAGG	910
AAD14	-----T-----	910
G16005	-----	583
U69884	-----A--C-----T-----A-----T-----	79
R69884	-----A--C-----A-----T-----A-----T-----	625
hSkca3	CCGAGACTGAGGGCCAAACCCCTCCAGCTTTTCAGCCCTAGCAACCCCCCGAGATCGTCATCTCCTCCCG	980
AAD14	-----	980
G16005	-----	653
U69884	-----C-----C-----T--C-----A-----TA-----A-----	149
R69884	-----C-----C-----T--C-----A-----TA-----A-----	695
hSkca3	GGAGGACAACCATGCCCAACAGACCTTGCTCCATCACCCTAATGCCACCCACAACCACCAGCATGCCGGC	1,050
AAD14	-----	1,050
U69884	-----T-----T-----C--C--T-----	219
R69884	-----T-----T-----C--C--T-----	765
hSkca3	ACCACCGCCAGCAGCACCACCTTCCCCAAGCCAACAAGCGGAAAAACCAAAACATTGGCTATAAGCTGG	1,120
AAD14	-----	1,120
U69884	-----T--TG-----	289
R69884	-----T--TG-----	835
hSkca3	GACACAGGAGGGCCCTGTTTGAAAAGAGAAAGCGACTGAGTGACTATGCTCTGATTTTGGGATGTTTGG	1,190
AAD14	-----	1,190
U69884	-G-----	359
R69884	-G-----	905
hSkca3	AATTGTTGTTATGGTGATAGAGACCGAGCTCTCTGGGGTTTGTACTCAAAGGACTCCATGTTTTCGTTG	1,260
AAD14	-----	1,260
U69884	-----A--G-----T-----	429
R69884	-----A--G-----T-----	975

FIGURE 1C

[illegible]

4/15

FIGURE 1D

hSkca3	AGCGGAGAAGCACGTGCATAACTTCATGATGGACACTCAGCTCACCAAGCGGATCAAGAATGCTGCAGCA	2,030
AAD14	-----CG-----	2,030
U69884	---A-----T-----C-----A-----C-----C-----C-----	1,199
R69884	---A-----T-----C-----A-----C-----C-----C-----	1,745
hSkca3	AATGTCCTTCGGGAAACATGGTTAATCTATAAACACACAAAGCTCCTAAAGAAGATTGACCATGCCAAAG	2,100
U69884	-----C-----C-G-----C-----C-----	1,269
R69884	-----C-----C-G-----C-----C-----	1,815
hSkca3	TGAGGAACACCCAGAGGAAGTTCCTCCAAGCTATCCACCAGTTGAGGAGCGTCAAGATGGAACAGAGGAA	2,170
U69884	---C-----T-----AC-----G-T-----A-----	1,339
R69884	---C-----T-----AC-----G-T-----A-----	1,885
hSkca3	GCTGAGTGACCAAGCCAAACACTCTGGTGGACCTTCCAAGATGCAGAATGTCATGTATGACTTAATCACA	2,240
U69884	-----C-----C-----C-----G-----G-----	1,409
R69884	-----C-----C-----C-----G-----G-----	1,955
hSkca3	GAACTCAATGACCGGAGCGAAGACCTGGAGAAGCAGATTGGCAGCCTGGAGTCCAAGCTGGAGCATCTCA	2,310
U69884	---G---C-----T-----A-----A---C-----C-----	1,479
R69884	---G---C-----T-----A-----A---C-----C-----	2,025
hSkca3	CCGCCAGCTTCAACTCCCTGCCCTGCTCATCGCCGACACCTGCCCCAGCAGCAGCAGCAGCTCCTGTC	2,380
U69884	---A-----T-----C-----A-----A-----G---CA-	1,549
R69884	---A-----T-----C-----A-----A-----G---CA-	2,095
hSkca3	TGCCATCATCGAGGCCCGGGGTGTCAGCGTGGCAGTGGGCACCACCCACACCCCAATCTCCGATACGCCC	2,450
U69884	---T---G-G-----CA---T---T---A---T-G---G---TCC---T---C-GC---T	1,619
R69884	---T---G-G-----CA---T---T---A---T-G---G---TCC---T---C-GC---T	2,165
hSkca3	ATTGGGGTCAGCTCCACCTCCTTCCCGACCCCGTACACAAGTTCAAGCAGTTGCTAAATAAATCTCCCCA	2,520
U69884	---C---A-----T-----GAATTCCTA-T-TTC-AG	1,689
R69884	---C---A-----T-----A-----A-----A-----	2,235
hSkca3	CTCCAGAAGCATTAAAAAAAAAAAAA	2,590
R69884	-----	2,305

FIGURE 2 A

[illegible]

6/15
FIGURE 2B

hSKCa3	HVONFMMGTQLTKRIKNAANVLRETWLIYKHTKLLKKIDHAKVRKHORKFLOATHQLRSVKMEQRKLSQ	630
U69884	-----H-----G-----	449
R69884	-----H-----G-----	630
AAD14 F3	-----	172
hSKCa3	QANTLVOLSKMQNVMYDLITELNDRSEDLEKQIGSLESKLEHLTASFNSLPLLIADTLROOQOQLLSAII	700
U69884	-----T-FV-----	519
R69884	-----T-FV-----	700
hSKCa3	EARGVSVAVGTHTPISDTPIGVSSTSFPPTPYTSSSSC	770
U69884	-----I-----S-A-P--S---I-----EFLIF	589
R69884	-----I-----S-A-P--S---I-----	770

Figure 3





Figure 4



9/15

FIGURE 5A

NUCLEOTIDE SEQUENCE AND TRANSLATION OF hKCa3

-286	-280	-270	-260	-250	-240
GCCTCA	CACGCTCCTA	GAGGACCACC	TCCTGAGAGA	GTTCTTTCAC	CCCCTCTTCT
-230	-220	-210	-200	-190	-180
TTCTCCAAGC	TCCGCTCCTG	CTCTCCCTCC	CTGCCCCAATA	CAATGCATTC	TTGAGTGGCA
-170	-160	-150	-140	-130	-120
CCGTCTGGAC	TCCAGGCAGC	CCCAGAGAAC	CGAAGCAAGC	CAAAGAGAGG	ACTGGAGCCA
-110	-100	-90	-80	-70	-60
AGATACTGGT	GGGGGAGATT	GGATGCCTGG	CTTTCTTTGA	GGACATCTTT	GGAGCGAGGG
-50	-40	-30	-20	-10	
TGGCTTTGGG	GTGGGGGCTT	GTGCTGCAGG	GAATACAGCC	AGGCCCCAAG	ATG GAC ACT Met Asp Thr

15	30	45	60
TCT GGG CAC TTC CAT GAC TCG GGG GTG GGG GAC TTG CAT GAA GAC CCC AAG TCC			
Ser Gly His Phe His Asp Ser Gly Val Gly Asp Leu Asp Glu Asp Pro Lys Cys			
75	90	105	
CCC TGT CCA TCC TCT GGG GAT GAG CAG CAG CAG CAG CAG CAG CAG CAG CAA CAG CAG			
Pro Cys Pro Ser Ser Gly Asp Glu Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln			
120	135	150	165
CAG CAG CCA CCA CCG CCA GCG CCA CCA GCA GCC CCC CAG CAG CCC CTG GGA CCC			
Gln Gln Pro Pro Pro Pro Ala Pro Pro Ala Ala Pro Gln Gln Pro Leu Gly Pro			
180	195	210	225
TCG CTC CAG CCT CAG CCT CCG CAG CTT CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG			
Ser Leu Gln Pro Gln Pro Pro Gln Leu Gln Gln Gln Gln Gln Gln Gln Gln Gln			
240	255	270	
CAG CAG CAG CAG CAG CCA CCG CAT CCC CTG TCT CAG CTC GCC CAA CTC CAG AGC			
Gln Gln Gln Gln Gln Pro Pro His Pro Leu Ser Gln Leu Ala Gln Leu Gln Ser			
285	300	315	330
CAG CCC CTC CAC CCT GGC CTG CTG CAC TCC TCT CCC ACC GCT TTC AGG GCC CCC			
Gln Pro Val His Pro Gly Leu Leu His Ser Ser Pro Thr Ala Phe Arg Ala Pro			
345	360	375	
CCT TCG TCC AAC TCC ACC GCC ATC CTC CAC CCT TCC TCC AGG CAA GGC AGC CAG			
Pro Ser Ser Asn Ser Thr Ala Ile Leu His Pro Ser Ser Arg Gln Gly Ser Gln			
390	405	420	435
CTC AAT CTC AAT GAC CAC TTG CTT GGC CAC TCT CCA AGT TCC ACA GCT ACA AGT			
Leu Asn Leu Asn Asp His Leu Leu Gly His Ser Pro Ser Ser Thr Ala Thr Ser			
450	465	480	495
GGG CCT GGC GGA GGC AGC CGG CAC CGA CAG GCC AGC CCC CTG GTG CAC CGG CGG			
Gly Pro Gly Gly Gly Ser Arg His Arg Gln Ala Ser Pro Leu Val His Arg Arg			

10/15

FIGURE 5B

510										525										540																			
GAC	AGC	AAC	CCC	TTC	ACG	GAG	ATC	GCC	ATG	AGC	TCC	TGC	AAG	TAT	AGC	GGT	GGG																						
Asp	Ser	Asn	Pro	Phe	Thr	Glu	Ile	Ala	Met	Ser	Ser	Cys	Lys	Tyr	Ser	Gly	Gly																						
555										570										585										600									
GTC	ATG	AAG	CCC	CTC	AGC	CGC	CTC	AGC	GCC	TCC	CGG	AGG	AAC	CTC	ATC	GAG	GCC																						
Val	Met	Lys	Pro	Leu	Ser	Arg	Leu	Ser	Ala	Ser	Arg	Arg	Asn	Leu	Ile	Glu	Ala																						
615										630										645																			
GAG	ACT	GAG	GGC	CAA	CCC	CTC	CAG	CTT	TTC	AGC	CCT	AGC	AAC	CCC	CCG	GAG	ATC																						
Glu	Thr	Glu	Gly	Gln	Pro	Leu	Gln	Leu	Phe	Ser	Pro	Ser	Asn	Pro	Pro	Glu	Ile																						
660										675										690										705									
GTC	ATC	TCC	TCC	CGG	GAG	GAC	AAC	CAT	GCC	CAC	CAG	ACC	CTG	CTC	CAT	CAC	CCT																						
Val	Ile	Ser	Ser	Arg	Glu	Asp	Asn	His	Ala	His	Gln	Thr	Leu	Leu	His	His	Pro																						
720										735										750										765									
AAT	GCC	ACC	CAC	AAC	CAC	CAG	CAT	GCC	GGC	ACC	GCC	GCC	AGC	AGC	ACC	ACC	TTC																						
Asn	Ala	Thr	His	Asn	His	Gln	His	Ala	Gly	Thr	Ala	Ala	Ser	Ser	Thr	Thr	Phe																						
780										795										810																			
CCC	AAA	GCC	AAC	AAG	CGG	AAA	AAC	CAG	AAC	ATT	GCC	TAT	AAC	CTG	GGA	CAC	AGG																						
Pro	Lys	Ala	Asn	Lys	Arg	Lys	Asn	Gln	Asn	Ile	Gly	Tyr	Lys	Leu	Gly	His	Arg																						
825										840										855										870									
AGG	GCC	CCG	TTT	GAA	AAG	AGA	AAG	CGA	CTG	AGT	CAC	TAT	GCT	CTG	ATT	TTT	GGG																						
Arg	Ala	Pro	Phe	Glu	Lys	Arg	Lys	Arg	Leu	Ser	Asp	Tyr	Ala	Leu	Ile	Phe	Gly																						
885										900										915																			
ATG	TTT	CGA	ATT	GTT	GTT	ATG	GTG	ATA	GAG	ACC	GAG	CTC	TCT	TGG	GGT	TTG	TAC																						
Met	Phe	Gly	Ile	Val	Val	Met	Val	Ile	Glu	Thr	Glu	Leu	Ser	Trp	Gly	Leu	Tyr																						
930										945										960										975									
TCA	AAG	GAC	TCC	ATC	TTT	TCG	TTG	GCC	CTG	AAA	TGC	CTT	ATC	AGT	CTG	TCC	ACC																						
Ser	Lys	Asp	Ser	Met	Phe	Ser	Leu	Ala	Leu	Lys	Cys	Leu	Ile	Ser	Leu	Ser	Thr																						
990										1005										1020										1035									
ATC	ATC	CTT	TTG	GGC	TTG	ATC	ATC	GCC	TAC	CAC	ACA	CGT	GAA	GCC	CAG	CTC	TTC																						
Ile	Ile	Leu	Leu	Gly	Leu	Ile	Ile	Ala	Tyr	His	Thr	Arg	Glu	Ala	Gln	Leu	Phe																						
1050										1065										1080																			
GTG	ATC	GAC	AAT	GGC	GCC	GAT	GAC	TGG	CGG	ATA	GCC	ATG	ACC	TAC	GAG	CGC	ATC																						
Val	Ile	Asp	Asn	Gly	Ala	Asp	Asp	Trp	Arg	Ile	Ala	Met	Thr	Tyr	Glu	Arg	Ile																						
1095										1110										1125										1140									
CTG	TAC	ATC	AGC	CTG	GAG	ATG	CTG	GTG	TGC	GCC	ATC	CAC	CCC	ATT	CCT	GGC	GAG																						
Leu	Tyr	Ile	Ser	Leu	Glu	Met	Leu	Val	Cys	Ala	Ile	His	Pro	Ile	Pro	Gly	Glu																						
1155										1170										1185																			
TAC	AAG	TTC	TTC	TGG	ACG	GCT	CGC	CTG	GCC	TTC	TCC	TAC	ACA	CCC	TCC	CGG	GCG																						
Tyr	Lys	Phe	Phe	Trp	Thr	Ala	Arg	Leu	Ala	Phe	Ser	Tyr	Thr	Pro	Ser	Arg	Ala																						

11/15

FIGURE 5C

1200 1215 1230 1245
GAG GCC GAT GTG GAC ATC ATC CTG TCT ATC CCC ATG TTC CTG CGC CTG TAC CTG
Glu Ala Asp Val Asp Ile Ile Leu Ser Ile Pro Met Phe Leu Arg Leu Tyr Leu

1260 1275 1290 1305
ATC GCC CGA GTC ATG CTG CTG CAC AGC AAG CTC TTC ACC GAT GCC TCG TCC CGC
Ile Ala Arg Val Met Leu Leu His Ser Lys Leu Phe Thr Asp Ala Ser Ser Arg

1320 1335 1350
AGC ATC GGG GCC CTC AAC AAG ATC AAC TTC AAC ACC CGC TTT GTC ATG AAG ACG
Ser Ile Gly Ala Leu Asn Lys Ile Asn Phe Asn Thr Arg Phe Val Met Lys Thr

1365 1380 1395 1410
CTC ATG ACC ATC TGC CCT GGC ACT GTG CTG CTC GTG TTC AGC ATC TCT CTG TGG
Leu Met Thr Ile Cys Pro Gly Thr Val Leu Leu Val Phe Ser Ile Ser Leu Trp

1425 1440 1455
ATC ATT GCT GCC TGG ACC GTC CGT GCC TGT GAA AGG TAC CAT GAC CAG CAG GAC
Ile Ile Ala Ala Trp Thr Val Arg Ala Cys Glu Arg Tyr His Asp Gln Gln Asp

1470 1485 1500 1515
GTA ACT AGT AAC TTT CTG CCT GCC ATG TGG CTC ATC TCC ATC ACA TTC CTT TCC
Val Thr Ser Asn Phe Leu Gly Ala Met Trp Leu Ile Ser Ile Thr Phe Leu Ser

1530 1545 1560 1575
ATT GGT TAT GGG GAC ATG GTG CCC CAC ACA TAC TCT CCC AAA GGT GTC TGT CTC
Ile Gly Tyr Gly Asp Met Val Pro His Thr Tyr Cys Gly Lys Gly Val Cys Leu

1590 1605 1620
CTC ACT GGC ATC ATG GGT GCA GGC TGC ACT GCC CTT GTG GTG GCC GTG GTG GCC
Leu Thr Gly Ile Met Gly Ala Gly Cys Thr Ala Leu Val Val Ala Val Val Ala

1635 1650 1665 1680
CGA AAG CTG GAA CTC ACC AAA GCG GAG AAG CAC GTT CAT AAC TTC ATG ATG GAC
Arg Lys Leu Glu Leu Thr Lys Ala Glu Lys His Val His Asn Phe Met Met Asp

1695 1710 1725
ACT CAG CTC ACC AAG CGG ATC AAG AAT GCT GCA GCC AAT GTC CTT CGG GAA ACA
Thr Gln Leu Thr Lys Arg Ile Lys Asn Ala Ala Ala Asn Val Leu Arg Glu Thr

1740 1755 1770 1785
TGG TTA ATC TAT AAA CAC ACA AAG CTG CTA AAG AAG ATT GAC CAT GCC AAA GTG
Trp Leu Ile Tyr Lys His Thr Lys Leu Leu Lys Lys Ile Asp His Ala Lys Val

1800 1815 1830 1845
AGG AAA CAC CAG AGG AAG TTC CTC CAA GCT ATC CAC CAG TTC AGG AGC GTC AAG
Arg Lys His Gln Arg Lys Phe Leu Gln Ala Ile His Gln Leu Arg Ser Val Lys

1860 1875 1890
ATG GAA CAG AGG AAG CTG AGT GAC CAA GCC AAC ACT CTG GTG GAC CTT TCC AAG
Met Glu Gln Arg Lys Leu Ser Asp Gln Ala Asn Thr Leu Val Asp Leu Ser Lys

FIGURE 5D

1905	1920	1935	1950
ATG CAG AAT GTC ATG TAT GAC TTA ATC ACA GAA CTC AAT GAC CGG AGC GAA GAC			
Met Gln Asn Val Met Tyr Asp Leu Ile Thr Glu Leu Asn Asp Arg Ser Glu Asp			
1965	1980	1995	
CTG GAG AAG CAG ATT GGC AGC CTG GAG TCG AAG CTG GAG CAT CTC ACC GCC AGC			
Leu Glu Lys Gln Ile Gly Ser Leu Glu Ser Lys Leu Glu His Leu Thr Ala Ser			
2010	2025	2040	2055
TTC AAC TCC CTG CCG CTG CTC ATC GCC GAC ACC CTG CGC CAG CAG CAG CAG CAG			
Phe Asn Ser Leu Pro Leu Leu Ile Ala Asp Thr Leu Arg Gln Gln Gln Gln Gln			
2070	2085	2100	2115
CTC CTG TCT GCC ATC ATC GAG GCC CGG GGT GTC AGC GTG GCA GTG GGC ACC ACC			
Leu Leu Ser Ala Ile Ile Glu Ala Arg Gly Val Ser Val Ala Val Gly Thr Thr			
2130	2145	2160	
CAC ACC CCA ATC TCC GAT AGC CCC ATT GGG GTC AGC TCC ACC TCC TTC CCG ACC			
His Thr Pro Ile Ser Asp Ser Pro Ile Gly Val Ser Ser Thr Ser Phe Pro Thr			
2175	2190	2205	2220
CCG TAC ACA AGT TCA AGC AGT TGC TAA ATA AAT CTC CCC ACT CCA GAA GCA TTA			
Pro Tyr Thr Ser Ser Ser Ser Cys *			
2235			
AAA AAA AAA AAA			

FIGURE 6

Alignment of cDNA and Genomic sequence of hKCa3
showing intron/exon boundary

	1140	1150	1160	1170	1180	1190
hKCa3f.seq	ACTGAGTGACTATGCTCTGATTTTGGGATGTTTGGGAATTGTTGTTATGGTGATAGAGA					
B1-1395.SEQ	ACTGAGTGACTATGCTCTGATTTTGGGATGTTTGGGAATTGTTGTTATGGTGATAGAGA					
	1200	1210	1220	1230	1240	1250
hKCa32f.seq	CCGAGCTCTCTTGGGGTTTGTACTCAAAGGACTCCATGTTTTCGTTGGCCCTGAAATGCC					
B1-1395.SEQ	CCGAGCTCTCTTGGGGTTTGTACTCAAAGGTAGGGGCTGTGGTTTCTCTTTATACCTTGA					
			↑	begin Intron 1		
B1-1395.SEQ	ACAAAAGGAATATGTAGGTAGCAAGAGAGGGATTGAGAGAGGGGGATATTGAGAGAGAGA					
B1-1395.SEQ	GAGAGAGAGAGAGAGAGAGATTGAGAGATTGGGAGGGAGACTGGGAGAGAGAGGTGGTGG					
B1-1395.SEQ	TGGTGGTGAGAGGCGCTTGCTCAGTTATAT					

FIGURE 7

Genomic map of hKCa3, first exon




FIGURE 8

5' Flanking/Untranslated sequence of hKCa3/KCNN3

CCC TTG AAC ACG AGG CGT TAG ACA CTC CAG TCC ATG 36
 GTA GGT TAG TTT TTA TCC NCC GGG GTG TTA GAA ACG 72
 TGG GNA TCC CCC CCT GGT TCT GTG ACC TTT GAC GTT 108
 GTT ACT CAA CAC CTT TTA AGC ATC AGG CTT TGT AAA 144
 TTG AGA CCA TAC TGG CCC ACC TCC TTG GGT GTT TGA 180
 AGA CTG TAT CCG GAT AAT ATA TGT GAA ACN ACC TAT 216
 CGT AAA CCC TGG TGG TTA ATA AAT GTT TGC CTT CCC 252
 CTC CGT CTG CCC CCT TCA TCC AGG GTG CAC ACC TCC 288
 CCT CCT TCG GAG GCC CTC TGT CCC TCC TCC CCA TCG 324
 CCC AGC GTG AGC GAA CAT CCC TTA TCG CCG TGG GCT 360
 TAA GGG TTG TGG CCA TAC CTG TCA GAG GAA AGA GGA 396
 CAG CGG CTC AGC TCC GGG GTG GGG GAG CAA AAA CTA 432
 CAG TTC CCA GTC CTC GCT GCG CCG CCA CTG GGG CCG 468
 GAG CCC AGG ACG CCA GGC CCC TCC TCT GGG GAG GAG 504
 CCT ATG CGG GGG GCG GAG CTA GGA GGA GGT TGG AGA 540
 GTT AAG CCA AGC CAA TGA GAC CAG CTG CTA ATA AGT 576
 GGG CTT GGC TTA CAA TGT AAC AGT GGC AGG AGG AGG 612
 CGA GCG AAG CTA TTG AGC CAG CGA GGA GTG AAG TGA 648
 GCC TGG CCT CAC ACG CTC CTA GAG GAC CAC 684

↑
 start of overlap with HSKCa3 cDNA sequence

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/14902

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/705, 16/28; C12N/1/20, 15/12; C12P 21/06; C12Q 1/68

US CL : Please See Extra Sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.2, 69.1, 252.3, 320.1; 514/2; 530/350, 388.22; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: potassium channel#, DNA, cDNA, clone?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y — A	KOHLER et al. Small-Conductance, Calcium-Activated Potassium Channels from Mammalian Brain. Science. 20 September 1996, Vol. 273, pages 1709-1714, especially Figures 1A and 1C on page 1710.	1-22, 24-33, 61, 62 ----- 23, 34-60, 63, 64



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 SEPTEMBER 1998

Date of mailing of the international search report

OCT 13 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN D. ULM

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/14902

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/6, 7.1, 7.2, 69.1, 252.3, 320.1; 514/2; 530/350, 388.22; 536/23.5

